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Nomenclature and abbreviations 
RNA - ribonucleic acid 
DNA - deoxyribonucleic acid 
CRISPR - clustered regularly interspaced short palindromic repeats 
TALENs - transcription activator-like effector nucleases 
DSB - double strand break 
NHEJ - non-homologous end joining 
HDR - homology directed repair 
PAM - protospacer adjacent motif 
PFS - protospacer flanking sequence 
RT-qPCR - real-time quantitative polymerase chain reaction 
amplicon - DNA sequence used as a source and product of the RT-qPCR 
crRNA - CRISPR RNAs 
tracrRNA - trans activating crRNA 
gRNA - guide RNA (crRNA + tracrRNA) 
protospacer - part of the crRNA that is complementary to the target 
Cas9 - CRISPR associated protein 9 
dCas9 - dead Cas9 











CRISPR/Cas systems have become a tool of choice for targeted genome engineering in 
recent years. Scientists around the world want to accelerate their research with the use 
of CRISPR/Cas systems, but are being slowed down by the need to understand the 
technology and computational steps needed for design and analysis. However, 
bioinformatics tools for the design and analysis of CRISPR experiments are being 
created to aid those scientists.  
 
For the design of CRISPR targeted genome editing experiments, CHOPCHOP has 
become one of the most cited and most used tools. After the initial publication of 
CHOPCHOP, our understanding of the CRISPR system underwent a scientific 
evolution. I therefore updated CHOPCHOP to accommodate the latest discoveries, such 
as designs for nickase and isoform targeting, machine learning algorithms for efficiency 
scoring and repair profile prediction, in addition to many others.  
 
On the other spectrum of genome engineering with CRISPR, there is a need for analysis 
of the data and validation of mutants. For the analysis of the CRISPR targeted genome 
editing experiments, I have created ampliCan, an R package that with the use of ‘editing 
aware’ alignment and automated normalization, performs precise estimation of editing 
efficiencies for thousands of CRISPR experiments. I have benchmarked ampliCan to 
display its strengths at handling a variety of editing indels, filtering out contaminant 
reads and performing HDR editing estimates.  
 
Both of these tools were developed with the idea that biologists without a deep 
understanding of CRISPR should be able to use them, and at the same time seasoned 
experts can adjust the settings for their purposes. I hope that these tools will facilitate 
adaptation of CRISPR systems for targeted genome editing and indirectly allow for 
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1.1. Genome Engineering 
 
Genomes encode the basis for all biological life on our planet. While we have yet to 
understand how genomes work in every detail, we have already discovered how to 
manipulate the genome in a variety of ways. Genome editing or genome engineering is 
widely defined as any kind of genome changing, whether it is to insert new 
deoxyribonucleic acid (DNA), remove part of the genome sequence, change bases or a 
mix of the above. Previously, changing of the genome was achieved in a stochastic 
fashion, through techniques like Agrobacterium-mediated transformation (Schell and 
Van Montagu 1977), transduction with viral vectors (Goff and Berg 1976), using 
restriction enzymes (Jeltsch et al. 1996; Schöttler et al. 1998) and mutagenesis induced 
with chemicals/UV (Russell et al. 1979; Kato, Rothman, and Clark 1977). Naturally, 
controlled and localized changes allow for more powerful experimental arrangements 
and have therefore been a focus of extensive research efforts over the years. 
 
Efforts for targeted genome editing were spurred by the discovery that some biological 
structures or mechanisms (guiding part) can recognize specific genomic sites based on 
their DNA sequence and introduce a double-stranded break (DSB) using its cutting 
mechanism (cutting part). The cells then activate their repair pathways, mainly non-
homologous end joining (NHEJ) or homology directed repair (HDR), which can repair 
the DSB. Although HDR is less error prone than NHEJ, both pathways sometimes make 
erroneous repairs. A possible change in the genome sequence prevents further binding 
of the guiding element. Using the above technique could lead to a loss-of-function allele 
(gene knock-out). Gene knock-outs can be used to determine the function of a particular 
gene in the cell. Furthermore, some DSBs can have ends with complementary sequences 
(called overhangs or sticky ends). The HDR pathway tries to fix DSBs with overhangs 
by using template sequence with complementary overhangs. Providing an artificial 
template with complementary overhangs is used in knock-in techniques to insert the 
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template into the genome sequence of interest. These prospects stimulated scientists to 
develop methods for targeted genome editing over the years. 
 
Decades of research resulted in a handful of techniques for editing at the desired 
location in the genome using various effectors, such as group 2 intron (Chen et al. 2005), 
Thermus thermophilus Argonaute protein (Swarts et al. 2014), structure-guided 
endonucleases (S. Xu et al. 2016), λ-bet/exo MAGE (K. Xu, Stewart, and Porter 2015; 
H. H. Wang et al. 2012), single-stranded oligodeoxyribonucleotides (Aarts and te Riele 
2010; Rios et al. 2012), and meganucleases (Donoho, Jasin, and Berg 1998). The most 
popular nucleases for targeted genome edits in chronological order has been zinc finger 
nucleases (ZFNs) (Y. G. Kim, Cha, and Chandrasegaran 1996), transcription activator-
like effector nucleases (TALENs) (Miller et al. 2011; F. Zhang et al. 2011), and finally 
clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) (Jinek et al. 
2012; Cong et al. 2013; Mali, Yang, et al. 2013; Hsu, Lander, and Zhang 2014). 
 
ZFNs and TALENs require the design and synthesis of the protein for each target locus, 
which is laborious and costly. CRISPR/Cas9 on the other hand has been demonstrated 
to require only its crRNA component - its guiding part - to be engineered for each locus. 
Other parts of the CRISPR/Cas9 system: the tracrRNA and Cas9 protein remain the 
same for every target of interest (Jinek et al. 2012; Cong et al. 2013; Mali, Yang, et al. 
2013; Hsu, Lander, and Zhang 2014). The synthesis of RNA is currently much cheaper, 
faster and less strenuous than the synthesis of proteins. Thanks to its simplicity, high 
editing efficiencies and relatively low time cost, CRISPR has become the method of 





Figure 1. PubMed registered manuscripts by keyword over years. CRISPR/Cas9 
genome editing is clearly the dominant strategy since 2013, even with “CRISPR/Cas9” 
as a strict keyword. The real number of publications that used CRISPR for genome 
editing applications is much higher since other terms were used. 
1.2. CRISPR 
1.2.1. Introduction to CRISPR/Cas9 
The journey for CRISPR research started with a discovery by Mojica et al. who 
discovered repeats in the genome of Haloferax mediterranei (F. J. Mojica, Juez, and 
Rodríguez-Valera 1993). Today, by Mojica’s suggestion, these clustered regularly 
interspaced short palindromic repeats are known as CRISPR array. The timeline of 
some of the key scientific findings leading to the CRISPR/Cas9 system are presented 
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Figure 2. Timeline of CRISPR discovery (Lander 2016). 
 
After many years of research, it became clear that CRISPR is a bacterial adaptive 
immune system (Figure 3), a genomic database to store previous viral aggressor 
footprints (F. J. M. Mojica et al. 2005; Pourcel, Salvignol, and Vergnaud 2005; Bolotin 





Figure 3. CRISPR as an adaptive immune system. Adapted from: James Atmos, 
distributed under a CC BY-SA 3.0 license. 
 
In 2005 it was found that the effector protein that has nuclease activity is Cas9 (Bolotin 
et al. 2005). Interestingly, Cas9 was expressed from cas-associated genes neighboring 
the CRISPR repeats. Bolotin also discovered that Cas9 recognizes its genomic targets 
using a protospacer adjacent motif (PAM). This PAM motif must be recognized by the 
Cas9 protein to activate cleavage, and because it is not present in the CRISPR database, 
the loci are safe from self-targeting. The next groundbreaking discovery was that the 
spacer sequences from the CRISPR array are transcribed into crRNAs (Brouns et al. 
2008). Two years later it was shown that crRNAs together with the tracrRNA form a 
duplex that guides Cas9 to its target (Deltcheva et al. 2011). All necessary parts of the 
CRISPR/Cas9 system were therefore known at this time. The Cas9 acts as the effector, 
cutting DNA, and the crRNAs and tracrRNA are the guiding part of the system. Reusing 
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this system in other prokaryotes (Sapranauskas et al. 2011) was the next major step that 
provided evidence that the system is transferable across species. Ideally, the guiding 
part of the system should be open for engineering to allow recognition of specific 
genomic loci. Reprogrammable guiding of Cas9 through changes in the guide RNA 
(gRNA) sequence was described in 2012 (Gasiunas et al. 2012; Jinek et al. 2012). 
Finally, using the CRISPR/Cas9 system in eukaryotic cells (human and mouse) enabled 
the release of the CRISPR/Cas9 system as a general genome engineering tool (Cong et 
al. 2013; Mali, Yang, et al. 2013).  
1.2.2. Elements of CRISPR/Cas9 system 
The CRISPR/Cas9 system is naturally composed of three elements: crRNA, tracrRNA 
and Cas9. Nowadays in genome engineering applications, crRNA and tracrRNA are not 
used as two distinct components, rather they are bridged by a GAAA tetraloop to form 
a single guide RNA (gRNA or sgRNA) (Jinek et al. 2012). The gRNA, or more 
precisely, its spacer part (Figure 4) together with the PAM, define the specificity of the 
system to the genomic location. The PAM is recognized by the Cas9 effector protein in 
the first step of target recognition. In the next step, high complementarity between the 
RNA spacer and the target DNA allows an R-loop to form, which in turn facilitates 
cleavage by Cas9 (Gasiunas et al. 2012). Cas9 uses a RuvC domain to cleave the non-
target DNA strand, and an HNH domain to cleave the complementary strand. Cleavage 
of Cas9 is blunt (no overhangs), and is localized 3-4 bp upstream of the PAM sequence. 
After the cut, Cas9 releases the DNA and continues to search for the next 
complementary target site until the protein is degraded. If there is another locus in the 
genome with a similar sequence to the spacer and PAM, that locus is also cleaved. Loci 
not accounted for during experiment design and incidentally cleaved by Cas9 are called 
off-target sites. Off-target sites are dangerous and risk the integrity of the experiment, 
but not all off-targets are cleaved efficiently. It is understood that different spacers have 
different cleavage efficiencies, therefore selection of an appropriate spacer is essential 






Figure 4. Elements of the CRISPR/Cas9 system. CRISPR/Cas9 protein (dark blue) 
searches the genome for the PAM (red NGG motif). If the spacer (purple, also called 
the guideRNA, gRNA, or sgRNA) and the genome sequence (protospacer) are 
complementary to each other, Cas9 will cleave 3-4 bp upstream of the PAM sequence 
using its RuvC domain for the non-complementary strand, and HNH domain for the 
complementary strand. 
1.2.3. CRISPR effectors 
CRISPR systems can be found in almost all archaea and in around 50% of bacteria 
(Hille et al. 2018). CRISPR/Cas systems are grouped into classes and further into types 
by: protein composition, effector complex structure, genome locus architecture, 
mechanisms of adaptation, pre-CRISPR crRNA processing and interference (Kira S. 
Makarova and Koonin 2013; Shmakov et al. 2015; K. S. Makarova, Wolf, and Koonin 
2018). Effectors from Class 2 are the simplest and most popular system to use with 
genome engineering in mind. CRISPR/Cas9 (type II) and CRISPR/Cas12a (type V) 
come from Class 2 as they are characterized by a single large protein effector. What’s 
more, many of the CRISPR/Cas types exist in multiple species, for example homologs 
with the same properties of CRISPR/Cas12a can be found in Prevotella, Francisella, 




During experimental design, scientists need to carefully select which CRISPR/Cas 
system to use, and from which species, as each species might have different PAM and 
gRNA requirements. For genome engineering applications, Cas protein effectors and 
gRNAs can be harvested and used outside of their adaptive immunity ecosystem. The 
most popular CRISPR effector currently used comes from Streptococcus pyogenes 
(Figure 4). Streptococcus pyogenes Cas9 is characterized by an NGG PAM and 
protospacer specificity towards 5’-20bp-NGG-3’. However, a plethora of other systems, 
with homologous Cas9 from other species exist, for example: Staphylococcus aureus 
defined by 5’-20bp-NNGRRT-3’ (Friedland et al. 2015; Nishimasu et al. 2015), or 
Streptococcus thermophilus with 5’-20bp-NNAGAAW-3’ (Garneau et al. 2010).  
 
Scientists search for novel classes and types of CRISPR/Cas systems, hoping for 
alternative functionality or sequence context specificity. Each of those systems might 
have different requirements for the PAM motif, allowing targeting of the genomic loci 
not previously accessible. For instance, Cas12a (formerly named Cpf1) class systems 
harvested from Acidaminococcus and Lachnospiraceae have 5’-TTTN-23bp-3’ as a 
PAM requirement, while creating an overhang cut - useful for homology-directed 
knock-in (Figure 5) (Zetsche et al. 2015). Additionally, targeting of RNA has also 
become possible with the recent discovery of Cas13a. The Cas13a system does not 
recognize a genomic PAM, but recognizes a PFS (protospacer flanking sequence) with 
the protospacer specificity defined as 5’-H-27bp-3’(Abudayyeh et al. 2017; Gootenberg 





Figure 5. Elements of the CRISPR/Cas12 system. CRISPR/Cas12 (formerly Cpf1) 
recognizes a TTTN motif downstream of the protospacer and creates an overhang cut. 
This system does not require a tracrRNA (Zetsche et al. 2015). 
1.2.4. Enzymatically dead Cas9 
Cas9 proteins have also been engineered to be enzymatically inactive (dead Cas9), 
while preserving the target recognition mechanism. Dead Cas9 (dCas9) can be used for 
gene repression by binding to the promoter region and inhibiting the gene transcription 
machinery from starting transcription. Additionally, a nickase system (Figure 6) (Mali, 
Aach, et al. 2013) can be adopted where two Cas9 proteins are used, each only 
introducing a single-strand DNA break. In the nickase system each of the Cas9 proteins 
has one of the cutting domains inactivated, which creates single strand damage when 
the Cas9 proteins are not targeting in close proximity. Using two single nicking Cas9s 
restricts the number of potential off-targets significantly as both target:spacer 
complexes have to be bound and active in close local and temporal proximity (B. Shen 
et al. 2014). Nickases also result in a DSB with long terminal overhangs, a preferred 




Figure 6. Elements of the CRISPR/Cas9 nickase system. Cas9 nickase is an approach 
where a mutated Cas9 can only create a cut on one of the two DNA strands. 
Consequently, two of those mutated Cas9 are necessary to create a much wider DSB, 
with an overhang resulting from the cut. This technique is much more resistant to off-
targets, but yields lower editing efficiency. 
1.2.5. CRISPR applications 
The most basic utility of the CRISPR system is to guide Cas9 protein (and its homologs) 
to a genomic locus of interest, where it induces DSBs that are repaired (often) 
erroneously by the cell repair pathways. This can cause the introduction of a frameshift 
mutation that knocks out a gene. 
 
A frameshift is a genetic mutation within the coding region of a gene caused by indels 
of a few nucleotides in a DNA sequence that is not divisible by three, which results in 
translation in a different frame to the original gene downstream of the mutation. If 
introduced towards the start of the gene the creation of a frameshift mutation is likely 
to render the gene non-functional and is therefore the desired outcome for gene knock-
out experiments.  
 
Introducing new sequence in the genome is also possible, which is the goal for knock-
in techniques. Knock-in efficiency can be improved by overhangs (“sticky ends”) which 
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can be created by chance after a DSB is introduced by Cas9. The chance of creating 
overhangs can be increased with the use of nickases or Cas12a. The donor sequence - 
with arms complementary to the overhangs - is used by the HDR to repair the DSB site 
(Nami et al. 2018). Alternatively, some approaches use very long complementary arms 
together with the use of regular Cas9 (J.-P. Zhang et al. 2017). 
 
With increased precision of genome targeting, it is now feasible to investigate the 
possibility of precision editing of the genome. Precision editing refers to the aim of 
editing a single nucleotide in the genome with high efficiency. This can for instance be 
achieved with the use of dead Cas9 fused with a cytidine deaminase that will alter C to 
U. This damage is recognized by cell-internal repair machinery and will be processed 
further to a T (Nishida et al. 2016; Komor et al. 2016). The field of precision editing 
using base editors is quickly developing: currently, it is also possible to create A to G 
conversions using Cas9 fused with adenosine deaminase (Gaudelli et al. 2017). In these 
methods, the recognition mechanism of Cas9 is unchanged, therefore the design of the 
gRNA for these experiments follows a similar path as for regular Cas9. 
 
Additionally, the use of dCas9 or Cas9 nickases together with different fusion proteins, 
allows for guided genome effectors, for example: base editing (Komor et al. 2016; 
Gaudelli et al. 2017), epitranscriptome modifications (Pulecio et al. 2017), GFP tagging 
(Lackner et al. 2015) and many more. Based on these techniques, more specialized 
applications have emerged, for instance: lineage tracing (Spanjaard et al. 2018), Oxford 
Nanopore sequencing enrichment (Gabrieli et al. 2018), detection of Zika virus 
(Gootenberg et al. 2018), gene drives (Kyrou et al. 2018), and many more, including 
medical applications. The discovery of CRISPR systems has revolutionized biology, 
and in the upcoming years will transform our everyday life. 
1.3. Design of CRISPR experiments 
Given such broad applications of the CRISPR systems there is a need for a 
comprehensive design for genomic and transcriptomic targeting. There are three main 
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components to consider for the successful design of a gRNA: the location of interest, 
potential off-target sites, and the efficiency of editing. 
1.3.1. Location 
Before carrying out a CRISPR experiment, the scientist has to decide the target, which 
can be a selected gene, a promoter site, or even a whole chromosome with many 
gRNAs. Knowing the location of interest, these genomic regions can be scanned for the 
presence of a PAM (depending on the CRISPR system used), to detect whether it is 
possible to target these loci. Generally, for each case, additional rules apply. For 
instance, the choice of location and by proxy, the sequence of the spacer has an 
influence on efficient editing (Doench et al. 2014; H. Xu et al. 2015). This is explained 
more in depth at heading 1.3.2. 
 
The choice of the precise locus to target depends on the experimental aim. For knock-
out experiments, it is beneficial to target the protein coding potential of the gene close 
to the start codon. At the same time, there is a chance of initiation at a start codon 
downstream of the cut site, which can result in a truncated, but potentially still 
functional protein. It is also usually preferable to design gRNAs that target all transcript 
isoforms of the gene to ensure complete knock-out of the gene.  
 
Knock-in experiments are highly dependent on the repair pathways and specific 
technique used. All knock-in methods involve preparation of microhomology arms of 
different lengths, which are context dependent (Nami et al. 2018). For approaches that 
use dCas9 for gene repression or activation, the region around the transcription start site 
is the preferred target, as CRISPR effectors can be used to block/unblock transcriptional 
machinery (Tanenbaum et al. 2014; Qi et al. 2013).  
 
Furthermore, for RNA base editing and RNA knock-down with Cas13 it has been 
shown that targeting the loop regions of folded transcripts is more efficient (Abudayyeh 
et al. 2016). For each experimental purpose many factors have to be considered to 
decide on the perfect gRNA location. 
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1.3.2. Specificity (off-targets) 
Off-targets are sites in the genome that are also targeted by the gRNA, but not 
intentionally. Finding all potential off-targets is important for all CRISPR experiments, 
as this ensures a predictable outcome of mutations in the cell. Methods such as: GUIDE-
Seq (Tsai et al. 2015), GOTI (Zuo et al. 2019), DISCOVER-Seq (Wienert et al. 2019) 
- can detect where the CRISPR effectors have cut in the genome after the experiment, 
and are the most reliable methods for experimental detection of off-target sites. 
However, experimental detection of the off-target sites is laborious, expensive and 
rarely done in practice. As an alternative, computational prediction is used to minimize 
the number of potential off-targets. 
 
Computational prediction can be performed by using sequence matching of the spacer 
to the genomic reference through alignment. It has been shown that even up to 6 
mismatches between the genomic target site (protospacer) and the RNA spacer can be 
tolerated by Cas9, although at very low editing efficiencies (Tsai et al. 2015; Xiaoling 
Wang et al. 2015). Searching the genome for spacer sequences with 0-3 mismatches has 
been shown to capture the majority of potential off-target editing (Tsai et al. 2015; 
Cameron et al. 2017). Searching for more mismatches costs computational time that is 
leveraged against the potential gain of detecting more off-target sites (Cameron et al. 
2017). A caveat with this however is that sites with many mismatches have a relatively 
small probability of being cut (Haeussler et al. 2016). A potential solution to this is 
present in a handful of off-target efficiency prediction algorithms that are able to score 
off-targets with the likelihood of a cut occurring at this given locus, taking into 
consideration the placement of mismatches on the off-target loci (Listgarten et al. 2018; 
Abadi et al. 2017). However, these algorithms carry the potential for false negative 
predictions, especially when off-target activity depends on the gRNA delivery method, 
cell type and duration of exposure to the effector protein (Cameron et al. 2017). Ideally, 
all genomic variation (e.g. single nucleotide polymorphisms, insertions) would be 
accounted for during the search for off-targets. This will become easier in the future 
with the widespread use of graph genomes for alignment, in combination with the use 
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of specialized aligners (Rakocevic et al. 2019). Another important aspect to consider 
comes from natural genomic variation. It is necessary to always include a control 
without CRISPR treatment for direct comparison in sequencing validation. When no 
controls are present, natural variation can be confused with successful targeted editing, 
or off-target activity.  
1.3.3. Efficiency 
An important feature of the CRISPR/Cas system is its overall high editing efficiency. 
However, the current level is not always sufficient for high precision interventions or 
experiments such as those needed in medical applications. Ensuring higher editing 
efficiencies with increased off-target fidelity than standard Cas9 with homolog/mutated 
effectors is therefore the focus of much active research (Moon et al. 2018; Kulcsár et 
al. 2017). Additionally, besides increasing efficiency through the design of new 
effectors, efficiency can also be computationally predicted using machine learning 
models allowing for the selection of highly efficient gRNAs (Doench et al. 2014).  
 
The efficiency of CRISPR editing is influenced by many factors. State-of-the-art 
machine learning approaches combine locus-specific information to create more 
accurate predictions of efficiency. Studies have shown that important features for 
efficiency prediction are chromatin accessibility (Uusi-Mäkelä et al. 2018), GC content 
of the guide (Ren et al. 2014; T. Wang et al. 2014; Wilson, O’Brien, and Bauer 2018), 
thermodynamic stability (Doench et al. 2014; Horlbeck et al. 2016), sequence of the 
spacer and surrounding region (Doench et al. 2016; H. K. Kim et al. 2018) and self-
complementarity (Thyme et al. 2016). Many of these studies provide machine learning 
models for predicting editing efficiency of the gRNAs. 
 
These models generally considered to be less important than off-target prediction 
models. This is because in the case of false negative off-target predictions, scientists 
have no way of knowing that their experiments are influenced while a gRNA that is 
inefficient will be detected. Another reason to give these models less weight is that, a 
recent study showed that these models are likely overfitting to their own dataset, and 
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might not be as robust for different experimental setups as expected, such as the use of 
different cell types, promoters, or different species (Haeussler et al. 2016). Additionally, 
far from all Cas9 homologs have their respective efficiency models pre-trained and 
available. In these cases, computing simplified features (e.g. GC content, self-
complementarity) might be the only possibility. Alternatively, assuming that a model 
trained on the close homolog will perform with similar robustness, is also possible.  
 
In summary, maximizing efficiency of editing and minimizing off-target effects is a 
task for in silico algorithms that score gRNAs for their experimental use. The ideal 
software should account for all developments in the field and be continuously upgraded. 
The use of CRISPR in genome engineering has grown spectacularly, and the number of 
software tools for gRNA design is overwhelming. The most cited tools include: 
CHOPCHOP (Montague et al. 2014; Labun et al. 2016; Labun, Montague, et al. 2019), 
Cas-OFFinder (Bae, Park, and Kim 2014), CRISPR-P (Lei et al. 2014; H. Liu et al. 
2017), E-CRISP (Heigwer, Kerr, and Boutros 2014), CRISPOR (Haeussler et al. 2016), 
CCTOP (Stemmer et al. 2017), and many more. Currently, there is a lack of 
comprehensive benchmarking and comparison of the tools to pinpoint which tools are 
good choices for each of the different experimental approaches, although some efforts 
are being directed there (Prykhozhij, Rajan, and Berman 2016; Bradford and Perrin 
2018; Cui et al. 2018). In the future, when more data is available, the tools should 
undergo more considerable benchmarking. Meanwhile, the tools should evolve to 
further facilitate genome editing. There is still room for improvement by inclusion of 
new features and scientific insights in the field. Many software tools are published with 
minimum features and after some time become deprecated and eventually abandoned. 
My goal for the CHOPCHOP tool was to not follow this path, but relentlessly enhance 
user experience through constant updates. 
1.4. Analysis of genome editing experiments 
After designing and executing a CRISPR experiment, verification of the mutation is 
standard practice. Among other methods, highly precise identification of CRISPR edits 
can be achieved using targeted next-generation sequencing of amplicons (NGS) 
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(Sentmanat et al. 2018). NGS amplicon sequencing allows for hundreds or thousands 
of experiments to be run in parallel, thanks to barcode demultiplexing techniques. 
However, the use of NGS for CRISPR editing validation is costly, and therefore applied 
when it is beneficial to identify precise allelic changes or when the costs can be reduced 
by scaling the experiment. NGS amplicon sequencing allows scientists to see which 
exact bases were changed, therefore allowing them to establish heterogeneity profile of 
the edits for each target site. Calculating the efficiency of base editors, incorporation 
rate of HDR or the frameshift rate should be possible when using NGS with a good 
processing pipeline. 
1.4.1. Editing efficiency estimation 
Calculation of CRISPR editing efficiency for every locus is the most basic measure of 
experiment success. Nonetheless, there are multiple confounding factors in precision 
estimation of that value. Use of a control group, without CRISPR editing, is necessary 
to remove all sample-specific bias. Ignoring the control group can result in paper 
retraction (Schaefer et al. 2017, 2018). There can be differences between the genomic 
reference and the genome of the organism used for the experiment. Not accounting for 
this difference can confound results by confusing natural SNPs with CRISPR edits.  
 
Another variable to consider is contaminant reads: reads that should not be considered 
when quantifying editing efficiency for a given locus (Lindsay et al. 2016). 
Contaminant reads might stem from high mosaicism, sequencing artifacts, formation of 
primer dimers, low quality reads, or erroneously assigned reads. For extremely precise 
editing efficiency estimation, sequencing noise (~ 0.1% for NGS) should also be taken 
into consideration. Additionally, in the case of paired-end read sequencing there can be 
biases connected to extracting the edited consensus from paired-end reads (Lindsay et 
al. 2016). Together, these confounding factors make the process of estimating editing 
efficiency more complicated than the matter would seem at first glance. 
 
In summary, given the scale of the NGS experiments, as well as the complexity of the 
experimental problem, specialized computational tools are needed to facilitate the 
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analysis of genome editing experiments. Multiple tools exist for the analysis of CRISPR 
experiments that use amplicon sequencing data, and new ones are emerging. To name 
a few that have full pipeline analysis: CRISPRAnalyzeR (Winter et al. 2017), ampliCan 
(Labun, Guo, et al. 2019), CrispRVariants (Lindsay et al. 2016), CRISPResso (Pinello 
et al. 2016; Clement et al. 2019) and CRISPRMatch (You et al. 2018). The main 
differences between these tools come from data processing choices and visualization. 
As the nature of the editing efficiency estimation problem is more quantifiable than the 
design for CRISPR editing, considerable benchmarking can be performed on those tools 
(Lindsay et al. 2016). However, tools for precise estimation of editing efficiency have 
been shown to have significant room for improvement. Tools compared by Lindsay et 
al. 2016 lacked automatic normalization of the data and used aligners that are not aware 
of how CRISPR editing differs from normal read mapping. This benchmark also did 
not consider estimations of HDR efficiencies. More specialized tools will hopefully be 








2. Aim of the thesis 
 
The potential of CRISPR has unleashed numerous new experimental approaches by use 
of precise genome targeting and engineering. Many scientists want to tap into what 
genome engineering has to offer, and use it to make a breakthrough in their own field. 
Current research on the CRISPR/Cas system is progressing at a frightening pace, 
unveiling new and unexpected applications, developing newer systems with interesting 
properties, as well as perfecting what is already known. Ideally, most scientists should 
not have to understand all of the intricacies of CRISPR to effectively use it. 
Computational tools come as an aid in this situation and nowadays are used for the 
design of CRISPR experiments, as well as the analysis of created mutants. 
 
CHOPCHOP was one of the first tools for the design of gRNAs for CRISPR/Cas9, 
published in 2014. As the field progressed at a staggering pace, it became necessary to 
update the tool with the latest developments, especially, when the user base is constantly 
growing. The first goal of my PhD was to provide a continuous update of CHOPCHOP 
with the latest developments in the field of CRISPR, related to the gRNA design. 
 
After the design of a gRNA - potentially using CHOPCHOP - and a successful 
laboratory application, the resulting data has to undergo bioinformatic analysis for 
editing validation. A high-throughput solution is to perform amplicon sequencing of the 
targeted locus. However, the experimenter needs to decide which tool to use for post-
sequencing data analysis. The second aim of my PhD was to create a comprehensive 
benchmark of tools that analyze amplicon sequencing data from targeted genome 
editing experiments. The third and final aim of my PhD was to create a tool for precise 








3. Summary of Results and Discussion 
 
Keeping CHOPCHOP up-to-date with CRISPR developments in the area of gRNA 
design is challenging as there are hundreds of papers published on this topic every year. 
The tool’s user base continues to grow and therefore it contains a great need for future 
developments. On the other spectrum of CRISPR experiments, benchmarking data 
analysis tools that estimate editing efficiency of CRISPR experiments was possible 
thanks to simulated datasets (where true editing efficiency is known). Therefore, I 
directed my benchmarking efforts there. To fill the gap for highly precise estimation of 
efficiency editing, I created ampliCan. 
 
Bullet points of achieved results and realized aims: 
1. Updated of the CHOPCHOP tool to include latest developments in the CRISPR 
field. 
1.1. Inclusion of Cas12a (formerly Cpf1) and homolog effectors. 
1.2. Addition of user defined PAM sequence, and user defined gRNA length. 
1.3. Scoring of gRNAs for nickase targeting. 
1.4. Extension with the algorithms for gRNA efficiency prediction. 
1.5. Searching for off-targets with a less specific ruleset. 
1.6. Incorporation of isoform targeting with Cas13. 
1.7. Preparation of basic modes for standard applications for less advanced 
users: knock-in, knock-out, knock-down, Nanopore enrichment, gene 
activation and repression. 
1.8. Extension with the algorithms for gRNA repair profile prediction. 
1.9. Implementation of isoform level resolution (intersection/union modes) 
and selection. 
1.10. Visual display presentation on the website of in-frame start codons and 
all isoforms. 
1.11. Creation of batch mode (design for many genes in a streamlined fashion) 




1.12. Preparation of queue to solve the congestion issue, arising due to growing 
number of users. 
1.13. Maintenance of user oriented service with efficient bug fixes, user support 
with the addition of novel genomes. 
2. Benchmarked tools for amplicon sequencing data analysis of genome editing. 
2.1. Reproduced previous benchmark from Lindsay et al. 2016. 
2.2. Characterized from where the differences between the leading tools arise 
when estimating true editing efficiency. 
2.3. Benchmarked how well leading tools can filter out contaminant reads. 
2.4. Determined how the type of editing event (deletion, insertion, mismatch, 
mixed) and its size is influencing error rates of the leading tools when 
estimating true editing efficiency. 
2.5. Performed separate evaluation for the estimation of the HDR editing 
efficiency of the leading tools. 
2.6. Discovered the depth of the precision that can be achieved when 
estimating the true editing efficiency on both real and simulated datasets. 
3. Implemented a tool that can outperform other benchmarked tools, and also 
adheres to the following points. 
3.1. Tool includes automatic use of the control data. 
3.2. Tool uses specialized alignments, optimized for genome editing. 
3.3. Software is able to capture longer indels as the result of genome editing. 
3.4. The tool allows for extremely precise estimation of true editing efficiency. 
3.5. Final output of the tool is, among other formats, aggregate reports of the 
gRNA activity. 
 
3.1. Updates of the CHOPCHOP tool 
When performing genome editing with CRISPR, scientists need to select gRNAs that 
have the highest potential DNA cutting efficiencies, and minimize potential off-target 
sites. In silico tools are supposed to help users make these choices. CHOPCHOP was 
one of the first tools (available as a web server and a Python script) for the design of 
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gRNAs for CRISPR experiments (Montague et al. 2014). In late 2015, I became 
involved in the CHOPCHOP project as one of the maintainers.  
 
With the attached paper Labun et al. 2016 (Paper I, aims 1.1-1.5), we extended 
CHOPCHOP with features related to the newly reported effectors. We implemented a 
5’ gRNA flanking type of PAM for applications with new effectors (e.g. Cas12) in 
addition to the 3’ PAM used by Cas9. Additionally, we created a nickase mode, 
adjustable gRNA length, and allowance for specification of any user defined PAM to 
answer growing scientific interest with discoveries of novel CRISPR effectors (Paper 
I). That development of CHOPCHOP allowed users to use the tool with future 
discoveries of novel CRISPR effectors. For instance, gRNAs for the recently discovered 
CasX (J.-J. Liu et al. 2019) could be designed with CHOPCHOP since the day CasX 
was discovered. 
 
CHOPCHOPs main difference in relation to other similar tools is that it is focused on 
integrating as much of the field knowledge as possible while maintaining flexibility of 
choice for more advanced users. CHOPCHOP was not created as just another efficiency 
scoring algorithm with a complimentary website and minimal set of features. On the 
contrary, CHOPCHOP incorporates published algorithms and currently supports 7 
efficiency scoring models (Doench et al. 2014, 2016; Moreno-Mateos et al. 2015; Chari 
et al. 2015; H. Xu et al. 2015; H. K. Kim et al. 2018; T. Wang et al. 2014). What's more, 
this is the only tool that computes self-complementarity of the sgRNA as well as its 
complementarity to the backbone region that can hinder editing efficiency (Thyme et 
al. 2016).  
 
GUIDE-Seq (Tsai et al. 2015) has shown that gRNAs can bind to off-target sites with 
up to 6 mismatches, but the majority of gRNAs that bind to potentially deleterious off-
target sites have up to 3 mismatches. To account for these findings, CHOPCHOP uses 
bowtie alignment (Langmead et al. 2009) to find potential off-targets with up to 3 
mismatches in the genome. This strategy balances computational time with sensitivity 




CHOPCHOP ranks gRNAs by their off-targets, efficiency, GC content and self-
complementarity to deliver a full list of potential spacers for a given locus. Every 
parameter of CHOPCHOP can be tuned for specific applications, but basic settings are 
also provided for users without detailed knowledge of the current developments in the 
field of CRISPR/Cas editing. User interaction was the main focus for the latest 
CHOPCHOP version (Paper II, aims 1.6-1.13). The aim of this publication was to 
increase use of CHOPCHOP by implementing optimized parameters and output for 
specific experimental approaches. CHOPCHOP now supports basic modes for gene 
knock-out, knock-in, repression/activation, nickases, Nanopore enrichment and knock-
down RNA targeting with Cas13 (aims 1.6, 1.7). With the latest update, CHOPCHOP 
also integrates prediction of the repair profile, which is one of the latest major 
developments in the field (M. W. Shen et al. 2018).  
 
After the recent update (Paper II), CHOPCHOP now displays all isoforms of the 
targeted gene together with all in-frame start codons (aim 1.10). Thus, CHOPCHOP is 
(to the author's knowledge) the only tool that supports isoform-aware gRNA design, 
which allows users to control targeting all isoforms of the gene of interest (aim 1.9). 
The visualization in CHOPCHOP promotes simplicity in gRNA choice, efficient primer 
design, as well as validation of editing outcome through restriction enzymes.  
Furthermore, CHOPCHOP has additional wrapper scripts (aim 1.11) that allow more 
advanced functionality: 1) batch mode - design and automatic selection of gRNAs for 
many genes at once; 2) control mode - design of gRNAs that have no putative targets 
on the genome. Since the tool’s creation, the CHOPCHOP maintainers have resolved 
countless requests from the growing user base. Implementation of the queue (aim 1.12) 
solved congestion issues on the web server. Meanwhile, constant additions and updates 
of genomes and their annotations accompanied both of the papers (Labun et al. 2016; 
Labun, Montague, et al. 2019). 
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Figure 7. CHOPCHOP users come from all over the world. The image above was 
generated by Google analytics attached to the web server, and shows the number of 
unique IP addresses that accessed website between 01.09.2016 and 11.08.2019: in total, 
over 115,897.
These updates increased the functionality of CHOPCHOP as gRNA design tool. At the 
time of writing, after three major releases (Montague et al. 2014; Labun et al. 2016; 
Labun, Montague, et al. 2019), CHOPCHOP is one of the most cited tools with 460 
citations for the first version and 245 for the second release. CHOPCHOP users come 
from all over the world, and there are hundreds of experiments being designed every 
day (Figure1,Figure 7). To date, CHOPCHOP stands as one of the most versatile and 
most curated tools for the design of CRISPR editing experiments.
3.2. Analysis of CRISPR amplicon sequencing data
Pipelines that process CRISPR data from amplicon sequencing should - at the very 
minimum - be precise at estimating true editing efficiencies. Tools that estimate editing 
efficiency exist and Lindsay et al. 2016 have created an interesting approach to 
benchmark other tools with an artificial dataset. Synthetic data was simulated based on 
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distributions of real editing events. Benchmarking on real data is problematic, as the 
ground truth (true editing efficiency) is not known. However, synthetic datasets offer a 
ground truth and thus allow direct comparison of tools. I have replicated the 
benchmarking performed in Lindsay et al. 2016 (Paper III, Supplemental Fig S7, aim 
2.1) to confirm their findings and include the tool that I have developed, ampliCan. The 
tools I compared were: ampliCan (Labun, Guo, et al. 2019), CrispRVariants (Lindsay 
et al. 2016), ampliconDIVider (Varshney et al. 2015), CRISPResso & CRISPResso 
Pooled (Pinello et al. 2016). The tools performed surprisingly unevenly on real datasets 
as well as on synthetic datasets (Paper III, Supplemental Note S1). Differences were 
proven to stem from processing choices: off-target detection, alignments and merging 
of the paired-end reads (aim 2.2). To highlight which method of data processing is the 
most robust, I simulated multiple other datasets (Paper III, Supplemental Table S2). 
With that, I established quantifiable metrics of how contaminant reads and different 
type of editing event can create problems with estimation of editing efficiency (Paper 
III, Fig II, aims 2.3-2.4). Since my benchmark, the developers of CRISPResso have 
published an updated version of their software (Clement et al. 2019). I have therefore 
recreated the benchmark for different types of reads with inclusion of the updated 
CRISPResso (Figure 8). CRISPResso v2 was run with docker technology and therefore 
there can be no mistake about improper installation of the software for the benchmark 
purposes. Issues with this tool are apparent in all benchmarks and it seems that the 
newer version has not yet addressed the pitfalls that caused the prior version to 
underperform. This example highlights the need for benchmarks in bioinformatics and 





Figure 8. Benchmark of the leading tools on editing events simulated from real data. 
Dotted line represents true editing rate for each sample and each locus is represented by 
one colored dot. ampliCan is the most consistent tool at calling larger indels as well as 
smaller edits. This figure is an unpublished update (includes CRISPResso v2) to the 
Supplemental Fig S11, Labun et al. 2019. 
 
Thanks to user feedback, ampliCan has also been extended with an HDR mode that is 
able to accommodate recognition and efficiency estimation of any intended editing, for 
example base editors and HDR insertions. Benchmarking estimation of HDR editing 
was a separate issue in which ampliCan was shown to outperform existing tools (Paper 
III, Supplemental Note S6, aim 2.5). Finally, I described the limit of the ampliCan 
approach in terms of precision. Estimating true editing efficiency in ampliCan is only 
restricted by the stochastic background noise of the sequencing procedure (~0.1%) as 
has been shown (Paper III, Supplemental Table S1), but even detection of events 
present in the frequency of 0.001% of NGS reads is possible (aim 2.6). With those 
considerable benchmarks I believe ampliCan has been proven as a comprehensive and 




It is challenging to derive true editing mutation efficiency without incorporation of the 
control data, especially in heterogeneous samples from many cells (Paper III, Fig 1 B-
C). ampliCan, to the author’s knowledge, was the first tool to include automatic 
normalization using control data. Furthermore, ampliCan does not merely subtract total 
editing efficiency of the control, which is common practice, but removes background 
events present in the control group from the treated group (Paper III, Supplemental 
Note S2, aim 3.1). 
 
ampliCan offers ways to manipulate the analysis at a fine grained resolution of a 
singular read event considering all edit events: mismatch, deletion or insertion. It also 
provides a full pipeline with default settings for less advanced users. What differentiates 
ampliCan from other tools is event-level manipulation rather than estimating 
efficiencies at the read level. This methodology allows users to filter out some of the 
events from the treated group - for instance editing events found in the controls - instead 
of filtering out reads themselves. ampliCan features a completely new approach for 
filtering contaminant reads using clustering, robustly rejecting primer-dimers, and 
rejecting off-target reads (Paper III, Supplemental Note S8, aim 2.3). ampliCan 
alignments are optimized for CRISPR editing (Paper III, Supplemental Note S3, aim 
3.2). Specialized alignments allow users to anticipate DSBs with the following repair, 
which allows them to also capture larger indels (Paper III, Supplemental Note S5, 
aim 3.3). ampliCan’s data processing allows for precise estimations of editing 
efficiency as shown on multiple benchmarks (Paper III, Fig 2, aim 3.4). In addition, 
ampliCan prepares complete and editable reports for the user, not only basic summary 
metrics of the editing efficiency rates (Paper III, Supplementary Note S7, aim 3.5). 
A layer of plots and figures composing reports can be seamlessly generated from the 
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ABSTRACT
In just 3 years CRISPR genome editing has trans-
formed biology, and its popularity and potency con-
tinue to grow. New CRISPR effectors and rules for
locating optimum targets continue to be reported,
highlighting the need for computational CRISPR tar-
geting tools to compile these rules and facilitate tar-
get selection and design. CHOPCHOP is one of the
most widely used web tools for CRISPR- and TALEN-
based genome editing. Its overarching principle is
to provide an intuitive and powerful tool that can
serve both novice and experienced users. In this ma-
jor update we introduce tools for the next generation
of CRISPR advances, including Cpf1 and Cas9 nick-
ases. We support a number of new features that im-
prove the targeting power, usability and efficiency of
CHOPCHOP. To increase targeting range and speci-
ficity we provide support for custom length sgR-
NAs, and we evaluate the sequence composition of
the whole sgRNA and its surrounding region using
models compiled from multiple large-scale studies.
These and other new features, coupled with an up-
dated interface for increased usability and support
for a continually growing list of organisms, maintain
CHOPCHOP as one of the leading tools for CRISPR
genome editing. CHOPCHOP v2 can be found at
http://chopchop.cbu.uib.no
INTRODUCTION
The discovery and adoption of the CRISPR bacterial sys-
tem for genome editing has led to a revolution in biology:
targeted mutations are now possible in a multitude of or-
ganisms, includingmany not previously amenable to genetic
manipulation. This has both transformed our approach to
answering biological questions and unlocked the possibility
of correcting human genetic diseases.
Originally harnessed from the Streptococcus pyogenes
type II system (1–3), CRISPR genome editing is based on a
two-component system: a Cas9 nuclease and a single guide
RNA (sgRNA), which directs the nuclease to a specific site
in the genome. In the presence of the sgRNA, Cas9 locates
the target site and makes a double-strand break (DSB). The
DSB is repaired by the host non-homologous end-joining
pathway, but often the repair is imperfect, creating indels
and in many cases frameshift mutations. Since the technol-
ogy’s inception, research to improve the technology has fo-
cused on two main challenges: optimization of cutting ef-
ficiency and specificity of cutting. A substantial portion of
sgRNAs designed for a given genewill produce a low or zero
cutting rate, and many sgRNAs have the capacity to bind
promiscuously in the genome, which can lead to off-target
mutagenesis (4–10). To address these issues, research has fo-
cused on identifying the sequence features that contribute to
effective (and ineffective) sgRNAs (11–16), as well as the de-
velopment of new CRISPR variants that expand the target-
ing range and specificity of the nuclease (17–20). With the
contribution of so many factors to optimum sgRNA tar-
get selection, it has become necessary to use software to aid
selection of CRISPR target sites for experiments. CHOP-
CHOP (21) provides an intuitive online environment for tar-
get selection that optimizes efficiency and specificity accord-
ing to the latest large-scale studies, as well as performing
primer design and restriction site identification, all in a user-
friendly, graphical interface (Figure 1). This new update of
CHOPCHOPprovides additional flexibility by offering new
options for sgRNA design, as well as additional metrics by
which sgRNA targets are scored and ranked.
IMPROVEMENTS IN THE 2016 RELEASE
CHOPCHOP accepts multiple input formats (gene iden-
tifiers, genomic coordinates and pasted sequences) for a
wide range of organisms, and provides instant, visual out-
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Figure 1. The workflow of CHOPCHOP in Cas9 nickase mode. The CHOPCHOP homepage (upper box) allows three types of input (DNA sequence,
genomic coordinates or gene IDs) with default parameters optimized for novice users. For experienced users, a number of options for Cas9, Cas9 nickase,
Cpf1 and TALENmode can be revealed. The results of the search (middle box) are displayed across the gene, genomic region or DNA sequence, depending
on the input format. The target color indicates the quality of each sgRNA or nickase pair (green [best] to red [worst]). The graphic representation of the
search area is complemented by an interactive table below (not shown). Each sgRNA or nickase pair can be explored in greater detail (lower box) with
annotated primer candidates and restriction sites, and information about any off-targets (not shown). Nickases are displayed in red and blue with the
intermediate region in black.
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put as well as downloadable data (GenBank, text tables and
FASTA files). In this new version users can also view the
output data in the UCSC browser (22) with a single click,
enabling results to be viewed in the context of annotated
genomic features, such as transcription factor binding sites
and chromatin architecture and accessibility (Figure 2).
CHOPCHOP offers flexible targeting to sub-regions of
protein-coding and non-coding genes, including coding re-
gions, UTRs, splice sites and individual exons. In this new
version we also offer a promoter-targeting mode (Figure
2) for experiments such as down- or upregulating gene ex-
pression using catalytically dead Cas9 (dCas9) or transcrip-
tionally active dCas9 (e.g. dCas9-VP64), respectively (23–
25). CHOPCHOP determines potential off-target sites for
all sgRNAs using Bowtie (26) and automatically generates
primers for target sites using Primer3 (27). The length and
annealing temperature of the primers, as well as the size of
the amplicon, can be specified. CHOPCHOP visualizes all
elements in a dynamic visual interface that includes infor-
mation about restriction sites, which can be used for down-
stream validation.
In addition to these improvements, the new iteration of
CHOPCHOP introduces the following major new features.
Support for a new generation of CRISPR effectors
The most widely used CRISPR effector is Cas9, derived
from the type II S. pyogenes system. While the RNA-
mediated targeting of Cas9 offers great versatility in select-
ing a target site, a limiting factor is the requirement for
an NGG protospacer adjacent motif (PAM) motif adja-
cent to the target. The occurrence of this motif is not rare
in most genomes, but it imposes a restriction that can be
inimical to achieving the high genomic precision required
for certain experiments, or for targeting small genes. The
new generation of CRISPR effectors vastly expands the
universe of viable targets by offering alternative PAM mo-
tifs (Supplementary Table S1, Supplementary Figures S1
and 2). CHOPCHOP now provides support for alternative
CRISPR effectors, including Cpf1 from Acidaminococcus,
which utilizes an AT-rich PAM (17) and Cas9 homologs
from S. pyogenes, Streptococcus thermophilus, Staphylococ-
cus aureus and Neisseria meningitidis (28). In addition,
CHOPCHOP also accepts user-defined custom PAMs that
can be anchored to the 5′ (Cpf1) or 3′ (Cas9) end of the
sgRNA. This field accepts the standard IUPAC nucleotide
alphabet (29), including ambiguity codes. CHOPCHOP
therefore provides support for the sequence requirements of
any currently known CRISPR effector and enables imme-
diate adoption of any new CRISPR effectors. This greatly
increases the targeting range of CRISPR experiments that
can be designedwith CHOPCHOP, including improved tar-
geting of AT-rich genomes such as Plasmodium falciparum
(Supplementary Figure S2).
New rules for optimizing cutting efficiency
CRISPR sgRNAs can be ranked by 2 criteria: (i)
efficiency––the likelihood that the particular sgRNA facil-
itates cutting, and (ii) specificity––the likelihood that the
sgRNA binds off-target sites.
The initial release of CHOPCHOP provided two sim-
ple metrics for efficiency based on experimental studies.
First, the GC-content of the sgRNA––ideally between 40
and 80%––and second, whether the sgRNA contains a G
at position 20 (11,30). Since the initial release of CHOP-
CHOP, several refinements have been proposed. A study
from Doench et al. produced a large dataset to calculate ef-
ficiencies across a wide range of sgRNAs (14), and the rules
for computationally-aided sgRNA design were recently fur-
ther refined by the same group (13). Moreno-Mateos et
al. conducted similar screens and found that sgRNA sta-
bility, which depends on guanine enrichment and adenine
depletion, was a major determinant of sgRNA efficiency
(12). Chari et al. conducted a study exploiting the bias of
lentiviral integration into transcriptionally active regions,
which: (i) revealed that accessible DNA ismore amenable to
cutting with Cas9; (ii) separated the influence of DNA ac-
cessibility and sequence composition on sgRNA efficiency.
CHOPCHOP users can now view results in the UCSC
browser (22) in the context of DNase I hypersensitivity sites
to predict accessible DNA regions (Figure 2). Finally, a
meta study by Xu et al. compiled the sequence specificities
across multiple datasets to build an aggregate model (15).
We have implemented all of these metrics in the new release
to give the user a broad selection of metrics to choose from
(the default is the Xu et al. metric). Using these methods,
CHOPCHOP can now score every sgRNA using position-
specific scoring matrices or support vector machines that
consider each individual position of the sgRNA as well as
the sequence downstream of the PAM and upstream of the
binding site. In the results table this score is reported as the
‘efficiency score’.
Other factors also play a role in whether an sgRNA is
likely to cut at its intended target. Recently, we and others
showed that self-complementarity of the sgRNA can inhibit
its efficient incorporation into the effector complex (12,31).
CHOPCHOP now includes the basic self-complementarity
score of the Thyme et al. study (31), which computes the
number of potential 4 bp stems within the sgRNA and be-
tween the sgRNA and the backbone. The user can therefore
opt to avoid sgRNAs with self-complementarity using this
option.
Strategies to increase specificity
A significant challenge in CRISPR experiments is the pos-
sibility of inducing cleavage at sites other than the intended
target. An emerging tool to alleviate this problem is the
paired nickase approach (32). Unlike natural CRISPR ef-
fectors, nickases have been modified to cut only one DNA
strand. In order to create a DSB, a pair of nickases must be
targeted to opposite strands and bind within 10–31 bp of
each other (32). These requirements vastly reduce the like-
lihood of creating off-target DSBs, and CHOPCHOP has
now added support for paired nickase experiments. In this
mode, sites on opposite strands within a specified distance
(either default or user-defined) are paired as potential nick-
ase sites. For these sites, in addition to the default off-target
search, each pair of sites is evaluated for off-targets where
binding and cutting would result in aDSB.Nickase sites are
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Figure 2. CHOPCHOP results can be exported to the UCSC browser with a single click. Here, the sgRNAs (in this example in promoter-targeting mode)
are viewed in the context of the genome. The tracks displayed in this example are DNase sensitive regions, common SNPs and CpG islands.
visualized with two CRISPR targets surrounding a ‘break’
region (Figure 1).
Recent studies have highlighted the need to search for
more than twomismatches when identifying off-targets (10)
so CHOPCHOP now counts off-targets with up to three
mismatches. While off-targets with more than three mis-
matches have been reported (10), evidence suggests that al-
most all predicted sites of four mismatches or more are not
cleaved (10) and therefore the vast majority of such pre-
dicted sites would be misleading and unnecessarily time-
consuming to search for during sgRNA selection.
Another strategy that has been shown to decrease off-
target cleavage is the use of truncated sgRNAs (10,20). Be-
sides increasing specificity, 5′ shortening of the customary
20 bp also increases the targeting range. The new version
of CHOPCHOP therefore provides support for sgRNAs of
user-defined lengths.
Thus, this version of CHOPCHOP supports a number of
new features that: (i) improve the ability to target a broader
range of sequences, and (ii) more thoroughly predict poten-
tial off-target sites in the genome. For an example of the
increased targeting range and additions to the scoring sys-
tem between the old and new versions of CHOPCHOP, see
Supplementary Figure S3 and Table S2.
New genomes
In addition to a new range of features, CHOPCHOP strives
to accommodate all requests for new genomes and gene an-
notation sets. So far we have incorporated all inquiries re-
ceived, and CHOPCHOP now supports a total of 32 organ-
isms. Furthermore, all genomes have been updated to their
most recent assemblies and suggestions for new species can
easily be submitted through a link on the main page.
DISCUSSION AND FUTURE DEVELOPMENTS
The overarching principle of CHOPCHOP is to provide an
intuitive and powerful tool that can serve first time as well as
experienced users. The basic mode offers optimized defaults
for the basic user, whilemore advanced users can select from
a wide range of options curated from the literature by their
relevance and utility. All options are presented in a tabu-
lated and organized manner to help users quickly visualize
and evaluate options when designing CRISPR experiments.
This release retains the general layout of the previous re-
lease, but updates the visual profile to a modern look and
to accommodate new features. The site is now mobile and
tablet friendly, and to streamline the user’s experience we
use cookies to remember the selection of species and tar-
geting options for subsequent searches. All reported bugs
have been fixed, and the implementation is now optimized
for future development to facilitate both rapid adoption of
any future effectors and new targeting data from large-scale
studies. This major update maintains CHOPCHOP as one
of themost easy-to-use, versatile and powerful CRISPR tar-
geting tools available.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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ABSTRACT
The CRISPR–Cas system is a powerful genome edit-
ing tool that functions in a diverse array of organ-
isms and cell types. The technology was initially de-
veloped to induce targeted mutations in DNA, but
CRISPR–Cas has now been adapted to target nu-
cleic acids for a range of purposes. CHOPCHOP is
a web tool for identifying CRISPR–Cas single guide
RNA (sgRNA) targets. In this major update of CHOP-
CHOP, we expand our toolbox beyond knockouts.
We introduce functionality for targeting RNA with
Cas13, which includes support for alternative tran-
script isoforms and RNA accessibility predictions.
We incorporate new DNA targeting modes, includ-
ing CRISPR activation/repression, targeted enrich-
ment of loci for long-read sequencing, and predic-
tion of Cas9 repair outcomes. Finally, we expand
our results page visualization to reveal alternative
isoforms and downstream ATG sites, which will aid
users in avoiding the expression of truncated pro-
teins. The CHOPCHOP web tool now supports over
200 genomes and we have released a command-line
script for running larger jobs and handling unsup-
ported genomes. CHOPCHOP v3 can be found at
https://chopchop.cbu.uib.no
INTRODUCTION
The use of CRISPR–Cas is now ubiquitous in modern
molecular biology. First introduced as a tool for introduc-
ing repair-induced mutations in the genome, the emergence
of catalytically dead or fused versions of the effector pro-
teins has transformed CRISPR–Cas into a general purpose
tool for targeting. For instance, CRISPR–Cas has been used
to introduce new sequences into the genome (1–3), activate
(4,5) or repress (6) transcription, as an enrichment tool for
sequencing (7,8), for targeted hypermutation (9), as a diag-
nostic tool (10), to perform whole-organism lineage tracing
(11), to target RNA molecules for destruction (12) or edit-
ing (13), and to track transcripts in live cells (14).
All CRISPR–Cas applications use a sgRNA to direct
the CRISPR effector (Cas) protein to its target. In theory,
CRISPR–Cas targeting only requires complementarity be-
tween the sgRNA and its nucleic acid target, but a num-
ber of studies have shown that efficient targeting follows
more complex rules (15–21). For instance, the position of
specific nucleotides in the target sequence, the accessibility
of the target site, and the sequence of its flanking regions
can all influence efficiency. The targeting efficiencies of Cas9
and Cas12a/Cpf1 have been measured in large-scale stud-
ies and combined with machine learning-based methods to
optimize cutting (15,21).
There are other factors that can influence or prevent the
generation of a null mutant. For instance, introducing a
frameshift mutation too close to the start codon can per-
mit translation initiation at a downstream ATG, leading to
unintentional protein production. In other cases, targeting
exons that are only present in a subset of isoforms can pre-
vent null mutation generation. Finally, CRISPR–Cas gene
editing can produce confounding phenotypes due to tran-
scription adaptation or genetic compensation. For instance,
a recent study showed that degradation of mutant mRNAs
could result in the upregulation of related genes (22). In
these situations, deleting the promoter can be a more robust
method to produce knockouts.
Many CRISPR–Cas applications require the generation
of a frameshift mutation to disrupt gene function, which re-
quires a DNA repair event in which the number of inserted
or deleted nucleotides is not a multiple of three. Surpris-
ingly, it has been shown that double-strand break (DSB) re-
pairs are not random: Cas9-induced DSBs using the same
sgRNA often give rise to the samemutations (23). Recently,
this has been incorporated into models that predict whether
DSB repairs will give rise to a frameshifting mutation (24).
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In summary, the CRISPR–Cas system has been adapted
for a wide selection of uses, and numerous factors influence
each of these modes, necessitating the existence of intuitive
software for target selection. This new update of the CHOP-
CHOP web tool incorporates new CRISPR–Cas targeting
modes and predicts frameshift mutation frequency in an im-
proved, user-friendly interface.
IMPROVEMENTS IN THE NEW RELEASE
Like previous versions, CHOPCHOPhandles input from (i)
gene and transcript identifiers, (ii) genomic coordinates and
(iii) pasted sequences, and provides results in a number of
output formats. The interface is simple (Figure 1) and re-
quires the user to make four selections in the default mode:
(a) target gene/isoform/region, (b) organism, (c) CRISPR
effector (e.g. Cas9, CasX or Cas13), and (d) purpose (e.g.
knockout, knockdown, repression). Advanced users can ad-
just the default settings by clicking the ‘Options’ button
(Figure 1).
While CHOPCHOP queries typically run within a few
seconds, heavy traffic can cause congestion during peak
hours. We have therefore introduced a queuing system that
ensures all users are prioritized. The new system retains re-
sults and calculations for up to 48 h after the initial query,
permitting quick access (via caching) if an identical search
is made later on and sharing results with collaborators. To
increase speed for larger queries, CHOPCHOP also sup-
ports pre-filtering of sgRNA targets by (i) GC content
(with a default of 10–90%) and (ii) the existence of self-
complementarity within the sgRNA. This can greatly re-
duce computation time.
Several adjustments have been made to improve the re-
sults page visualizations. Notably, in-frame downstream
ATGs are now colored in the isoform visualization (Figure
1) to help users avoid downstream translation initiation. In
addition, the results table can now be sorted using any cri-
teria.
In addition to these improvements, the latest CHOP-
CHOP introduces the following new major features.
Targeting the transcriptome
The most widespread use of CRISPR–Cas is to intro-
ducemutations intoDNA.However, CRISPR–Cas systems
have now been engineered to target RNA. For instance,
CRISPR–Cas13 has been harnessed for transcript knock-
down (25), live-cell transcript imaging (14) and RNA base
editing (13).
CHOPCHOP now permits CRISPR–Cas13 targeting,
and implements this functionality by searching for off-
targets across the complete transcriptome rather than the
genome. An important aspect of RNA targeting is to avoid
regions of high structure that can reduce the accessibility
of Cas13 (12,14,26). CHOPCHOP calculates RNA acces-
sibility using RNAfold from the ViennaRNA package (27)
according to published recommendations (14). Briefly, ac-
cessibility is calculated in windows of 70 nucleotides, ob-
taining the probability that a given nucleotide position in
the transcript is unpaired. For each target, we take themean
probability of structure across each position targeted by the
sgRNA (14).
Similar to protospacer adjacent motifs (PAMs) in DNA-
targeting modes, we support any 5′ or 3′ protospacer flank-
ing sequences (PFS) for RNA targeting. The Cas13a PFS
- an H at the 3′ end of the target - is the default. As with
the PAM, the PFS should be present in the sequence of the
DNA or RNA target, but not in the sgRNA. CHOPCHOP
provides the appropriate sgRNA sequence, ensuring that
the user does not include the PFSwhen ordering the sgRNA
oligonucleotide.
New modes for targeting the genome
CHOPCHOP v3 expands the number of modes for DNA
targeting. These include: (i) Nanopore enrichment mode.
Targeted sequencing is a method used to attain high quality
sequencing reads in a specific region of interest. PCR-based
methods for enriching genomic regions have some limita-
tions, for instance the maximum length of the region that
can be enriched. By contrast, CRISPR–Cas provides a pow-
erful method to excise genomic regions prior to amplifica-
tion and sequencing with Oxford Nanopore Technologies
(ONT) (7,8). The nanopore enrichment mode in CHOP-
CHOP allows users to identify pairs of gRNAs flank-
ing large regions (up to 40kb) by excluding low-efficiency
guides. The mode filters all sgRNAs with predicted self-
complementarity, as this can have inhibitory effects on
global Cas9 activity (8,28 and ONT personal communica-
tion); (ii) Knock-in mode. This identifies the same sgRNAs
as the knockout mode, but designs homology arms up to 2
kb, which, based on recent studies (1–3) can be used for tar-
geted insertions; (iii) Activation/repression modes. These
modes are designed for use with Cas9 fusion proteins with
the intention of activating or repressing a gene. Specifically,
the modes target the promoter region and its flanking sites
according to the guidelines specified in (29–31) in order to
bring the activating/repressing domain into close proximity
with the transcription start site.
For the Cas9 knockout mode, we now create a predic-
tion of DSB repair outcomes (24). The model estimates the
probability that a given sgRNA will result in a frameshift
mutation. In addition, we have added efficiency scores
for Cas12a/Cpf1 (21) and updated the ‘Doench’ efficiency
score to the newest version (15), which is now the default
scoring metric for Cas9 genomic targeting.
Expansion of genomes and targeting
CHOPCHOP now supports over 200 genomes and includes
gene annotations for genomic targets, as well as three tran-
scriptomes for RNA knockdown (human, mouse and ze-
brafish). While previous versions of CHOPCHOP required
the selection of a specific isoform for targeting, this new ver-
sion allows the user to target the entire gene. In its default
‘intersection’ mode, CHOPCHOP v3 only searches for sgR-
NAs present in every isoform (Figure 1). This mode can be
disabled by selecting the ‘union’ mode, which will display
all sgRNAs in all transcripts, as well as a column indicating
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Figure 1. The workflow of CHOPCHOP when targeting RNA for knock-down. The CHOPCHOP homepage (upper box) require four types of input: (i)
target, (ii) species, (iii) CRISPR effector and (iv) the purpose of the experiment. Default options will be adequate for most users, but advanced options
can be revealed using the ‘Options’ button. The results of the search (lower box) are displayed along with all isoforms of the target gene. The target color
indicates the quality of each sgRNA or nickase pair (green [best] to red [worst]). Below the graphic representation an interactive table allows for exploring
each guide in greater detail.
Command-line version
In addition to the web interface, we also provide the code
for the command-line version of CHOPCHOP, which can
be run locally and is suited for larger queries or screens.
This tool includes all of the functionality of the web in-
terface in addition to extra functionality for larger exper-
iments, such as the ability to design control sgRNAs that
do not match any sequence in the genome. The command-
line version of CHOPCHOP is compatible with ampliCan,
a tool for sequencing-based assessment of mutations (32).
DISCUSSION AND FUTURE DEVELOPMENTS
Since its inception, the CRISPR field has undergone con-
stant and rapid innovation, requiring the parallel devel-
opment of bioinformatic tools that accommodate the new
findings and technologies. In just a few years, CRISPR–Cas
has become a powerful targeting tool for silencing and ac-
tivating both DNA and RNA in a range of contexts, each
of which requires the application of specific rules. The latest
release of CHOPCHOP addresses this challenge by adding
new functionalities that reflect the ever-expanding CRISPR
toolbox. So far, we have accommodated the favorite species
of over 200 research groups, and as we continue to improve
the functionality of CHOPCHOP, we will continue to ac-
commodate new transcriptomes and genomes.
In conclusion, this major update expands the CHOP-
CHOP toolbox, retaining its position as one of the most
easy-to-use, versatile CRISPR–Cas targeting tools avail-
able.
DATA AVAILABILITY
The CHOPCHOP (version 3) server is available at https://
chopchop.cbu.uib.no; the python code for local installation
is available at https://bitbucket.org/valenlab/chopchop.
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We present ampliCan, an analysis tool for genome editing that unites highly precise quantification and visualization of
genuine genome editing events. ampliCan features nuclease-optimized alignments, filtering of experimental artifacts,
event-specific normalization, and off-target read detection and quantifies insertions, deletions, HDR repair, as well as target-
ed base editing. It is scalable to thousands of amplicon sequencing–based experiments from any genome editing experiment,
including CRISPR. It enables automated integration of controls and accounts for biases at every step of the analysis. We
benchmarked ampliCan on both real and simulated data sets against other leading tools, demonstrating that it outper-
formed all in the face of common confounding factors.
[Supplemental material is available for this article.]
With the introduction of CRISPR (Jinek et al. 2012; Cong et al.
2013), researchers obtained an inexpensive and effective tool for
targeted mutagenesis. Despite some limitations, CRISPR has been
widely adopted in research settings and has made inroads into
medical applications (Courtney et al. 2016). Successful genome ed-
iting relies on the ability to confidently identify inducedmutations
after repair through nonhomologous end-joining (NHEJ) or ho-
mology directed repair (HDR). Insertions or deletions (indels) are
often identified by sequencing the targeted loci and comparing
the sequenced reads to a reference sequence. Deep sequencing
has the advantage of both capturing the nature of the indel,
readily identifying frameshiftmutations or disrupted regulatory el-
ements, and characterizing the heterogeneity of the introduced
mutations in a population. This is of particular importance when
the aim is allele-specific editing or the experiment can result in
mosaicism.
The reliability of a sequencing-based approach is dependent
on the processing and interpretation of the sequenced reads and
is contingent on factors such as the inclusion of controls, the
alignment algorithm, and the filtering of experimental artifacts.
To date, no tool considers and controls for the whole range of bi-
ases that can influence this interpretation and, therefore, distort
the estimate of the mutation efficiency and lead to erroneous con-
clusions. Here we introduce a fully automated tool, ampliCan, de-
signed to determine the true mutation frequencies of CRISPR
experiments from high-throughput DNA amplicon sequencing.
It scales to genome-wide experiments and can be used alone or in-
tegrated with the CHOPCHOP (Montague et al. 2014; Labun et al.
2016) guide RNA (gRNA) design tool.
Results
ampliCan accurately determines the true mutation efficiency
Estimation of the true mutation efficiency depends on multiple
steps all subject to different biases (Lindsay et al. 2016). Following
sequencing, reads have to be aligned to the correct reference and
filtered for artifacts, and then the mutation efficiency has to be
quantified and normalized (Fig. 1A). In most existing tools,
many of the choices made during these steps are typically hidden
from the user, leading to potential misinterpretation of the data.
These hidden steps can lead to widely different estimates of muta-
tion efficiency (in up to 67% of all experiments) when run on data
from real experiments (Supplemental Note S1; Supplemental Fig.
S1). Furthermore, steps are frequently relegated to other tools
that have not been optimized for CRISPR experiments. ampliCan
instead implements a complete pipeline from alignment to inter-
pretation and can therefore control for biases at every step.
Despite being arguably themost important step in any exper-
iment, the use of controls is frequently overlooked in CRISPR as-
says. Discrepancies between a reference genome and the genetic
variation in an organism of interest often lead to false positives
and the false impression that mutations have been introduced
(Gagnon et al. 2014). Although the use of controls is (in principle)
possible with any tool, it commonly requires running the treated
and control samples separately followed by a manual inspection
and comparison. In ampliCan, controls are an integrated part of
the pipeline, and mutation frequencies are normalized and esti-
mated automatically. ampliCan accomplishes this by normalizing
at the level of editing events (insertion, deletion, or mismatch)
rather than at the level of whole reads. This means that any puta-
tive editing event detected in the reads from the target sample that
also occurs in the reads from the control sample, above the level of
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noise, is ignored when calculating mutation frequencies. Impor-
tantly, this normalization process does not remove any reads
from the calculation; it only refrains from counting the specific ed-
iting events that are also present in the controls (Supplemental
Figs. S2–S4; Supplemental Table S1). Therefore, it also does not fil-
ter any genuine editing events that may co-occur on the same read
as a normalized event (see Supplemental Note S2). This process is
blind to the source of the event, which may include genetic vari-
ance as well as experimental and sequencing artifacts. To assess
the impact of controls, we generated 112 CRISPR data sets and
pooled them with data we previously generated (Gagnon et al.
2014) for a total of 263 experiments (Methods; Supplemental
Note S1; Supplemental Table S2). These consisted of pools of
CRISPR-injected zebrafish using wild-type fish as a control. This
experimental setup presents a challenging task to pipelines
because the genetic background may not be identical across all
fish and because the injected fish can be highly mosaic in their
mutational outcomes. This benchmark revealed that accounting
for the genetic background in the wild-type fish reduced the esti-
mated mutation frequencies substantially in several experiments
and is a necessary step to ensure accurate results (Fig. 1B,C; Supple-
mental Fig. S5).
Estimating mutation efficiency starts with the alignment of
the sequenced reads (Fig. 1A). A common strategy is to use stan-
dard genomic alignment tools. However, these tools do not align
using knowledge about the known mechanisms of CRISPR-in-
duced double-stranded breaks and DNA repair. Genome editing
typically results in a single deletion and/or insertion of variable
length. Hence, correctly aligned reads will often have a low num-
ber of events (optimally one deletion and/or one insertion after
normalization for controls) overlapping the cut site, whereas mis-
aligned readswill result in a highnumber of events throughout the
read owing to discrepancies to the correct loci. Therefore an align-
ment strategy that penalizesmultiple indel events (seeMethods) is
more consistent with DNA repair mechanisms and the CRISPR
mode of action. ampliCan uses the Needleman–Wunsch algo-
rithm with tuned parameters to ensure optimal alignments of
the reads to their loci and models the number of indel and mis-
match events to ensure that the reads originated from that loci
(see Methods; Supplemental Note S3). In contrast, nonoptimized
aligners can create fragmented alignments, resulting inmisleading
mutation profiles and possible distortion of downstream analyses
and frameshift estimation (Supplemental Fig. S6). In assessments,
ampliCan outperforms the tools CrispRVariants, CRISPResso, and
ampliconDIVider on the synthetic benchmarking previously used
to assess these tools (Lindsay et al. 2016), in which experiments
were contaminated with simulated off-target reads that resemble
the real on-target reads but have a mismatch rate of 30% per
base pair (Supplemental Fig. S7). A cause for concern is that the
mapping strategy used in the pipelines of several tools (Sup-
plemental Table S3) is not robust to small perturbations of this
mismatch rate, and when we simulated contaminant off-target
A B
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Figure 1. Overview of ampliCan pipeline and normalization. (A) Estimation ofmutation efficiency consists of multiple steps. At each of these steps, biases
can be introduced. Controls are processed identically to the main experiment and used for normalization. (B) Overview of the change in estimated mu-
tation efficiency on real CRISPR experiments when using controls that account for natural genetic variance in 29 experiments (mean change of 30%).
Red dots show initial estimates based on unnormalized data, whereas black dots show the values after normalization. (C ) Alignment plot showing the
top 10 most abundant reads in a real experiment. The table shows relative efficiency (Freq) of read, absolute number of reads (Count), and the summed
size of the indel(s) (F), colored greenwhen inducing a frameshift. The bars (top right) show the fraction of reads that contain no indels (Match), those having
an indel without inducing frameshift (Edited), and frameshift-inducing indels (F). The left panel shows the estimated mutation efficiency from raw reads,
which is 14% (11% with frameshift, 3% without). The right panel shows the same genomic loci after normalization with controls, resulting in a mutation
efficiency of 0%. The deletion of 11 bp in 9% of the reads could not be found in the GRCz10.88 Ensembl Variation database and would, in the absence of




data with varying degrees of mismatches to the on-target loci (see
Supplemental Note S4), it led to a significant reduction in perfor-
mance (Fig. 2, left). In contrast, ampliCan’s strategy of modeling
editing events to ascertain whether a read originated from the
on-target or the off-target loci resulted in consistently high perfor-
mance across a broad range of mismatch rates (Fig. 2, left; Supple-
mental Figs. S7, S8).
ampliCan can detect long indels and estimate HDR efficiency
Targeted insertion of shorter fragments through co-opting of the
homology directed repair (HDR) pathway is becoming increasingly
popular (Lackner et al. 2015; Kuscu et al. 2017). This, together with
long indels occurring in regular CRISPR experiments (Supplemen-
tal Figs. S9, S10), presents a challenge for most CRISPR analysis
tools. To assess the ability of the leading tools in recognizing
long indels, we simulated data using the strategy from Lindsay
et al. (2016), but restricted to indels of ≥10 bp. This revealed an in-
ability of current pipelines to process these longer events (Fig. 2,
right), typically stemming from alignment strategies that are un-
able to assign reads with long indels to the correct loci. In previous
assessments, simulated data have often been restricted to short
indels in which this weakness would not be apparent (Supplemen-
tal Note S5). By using a localized alignment strategy, based on
primer matching (see Methods), ampliCan knows a priori which
loci the reads are supposed to originate from. This alignment strat-
egy therefore outperforms all other tools and robustly handles
these longer indels (>10 bp) when they occur unintentionally
(Fig. 2, right; Supplemental Fig. S11).
Intentional introduction of specific edits using donor tem-
plates is supported in ampliCan through an HDR mode in which
it first aligns the donor template to the reference in order to iden-
tify editing events that are expected to take place in a successful in-
tegration. The presence of these success-events is then quantified
in the edited samples, obtaining the frequency of integration. To
assess this strategy, we simulated experiments with different levels
of donor integration (a result of HDR) in the presence of different
levels of cut loci but with donor introduction (a result of nonho-
mologous end-joining [NHEJ]). This revealed that only ampliCan
can consistently recover both the true HDR and NHEJ efficiency
(Supplemental Note S6; Supplemental Fig. S12). An identical strat-
egy also makes it possible to quantify the efficiency of base editors
(Komor et al. 2016; Gaudelli et al. 2017) by supplying ampliCan
with templates in which the target bases have been altered.
ampliCan summarizes and aggregates results over
thousands of experiments
To aid analysis of heterogeneous outcomes, ampliCan quantifies
the heterogeneity of reads (Supplemental Fig. S13), the complete
mutation efficiency for an experiment, and the proportion of mu-
tations resulting in a frameshift (Fig. 1C, top right). It also aggre-
gates and quantifies mutation events of a specific type if a
particular outcome is desired (Supplemental Fig. S14). In addition,
ampliCan provides overviews of the impact of all filtering steps
(Supplemental Figs. S15, S16). Reports can be generated in several
formats (Supplemental Tables S4, S5) and aggregated at multiple
levels such as sequencing barcodes, gRNA, gene, loci, or any user-
specified grouping (Supplemental Note S7). This enables explora-
tion of questions beyond mutation efficiency such as the rules of
gRNA design, whether a particular researcher is better at designing
gRNAs than others (Supplemental Fig. S17), whether a given bar-
code is not working, or determining the stochasticity in the muta-
tion outcome from a given gRNA (Supplemental Fig. S18).
Discussion
ampliCan offers a complete pipeline for genome engineering con-
trolling for biases at every step of evaluation. When used with
CRISPR, it can be integrated with the CHOPCHOP tool for gRNA
design to incorporate all computational steps necessary for a
CRISPR experiment. It scales from a single experiment to ge-
nome-wide screens and can be run with a single command. For
more advanced users, it provides a complete and adaptable
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Figure 2. Benchmark of leading tools when estimating mutation efficiency under different data set conditions. Each dot shows the error of the estimate
to the correct value for a single experiment normalized to a 0–100 scale. Themedian performance (mixed indels) is indicated by the horizontal line. The left
panel shows comparison of tools when data sets contain contaminant reads (see text and Methods). The x-axis denotes how dissimilar the contaminant
reads are to the correct reads. In cases in which the contaminants are from homologous regions, this may be low (10%); for other contaminants, this is likely
to be higher (30%). The right panel shows performance of tools as a function of the length of indel events. The sets in the first column contain no indels
>10 bp; the second column (Mixed indels) contains a mix of shorter and longer events; the sets in the third and fourth columns contain insertions and
deletions >10 bp, respectively.
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framework, enabling further exploration of the data. Collectively,
these advances willminimizemisinterpretation of genome editing




ampliCan is completely automated and accepts a configuration file
describing the experiment(s) and FASTQ files of sequenced reads as
input. The configuration file contains information about bar-
codes, gRNAs, forward and reverse primers, amplicons, and paths
to corresponding FASTQ files (Supplemental Table S6). From
here, ampliCan generates reports summarizing the key features
of the experiments.
In the first step, ampliCan filters low-quality reads that have
either ambiguous nucleotides, an average quality, or individual
base quality under a default or user-specified threshold (Supple-
mental Note S8). After quality filtering, ampliCan assigns reads to
the particular experiment by searching for matching primers (de-
fault up to twomismatches, but ampliCan supports different strin-
gency) (Supplemental Note S9). Unassigned reads are summarized
and reported separately for troubleshooting. After read assign-
ment, ampliCan uses the Biostrings (https://bioconductor.org/
packages/release/bioc/html/Biostrings.html) implementation of
the Needleman–Wunsch algorithm with optimized parameters
(gap opening=−25, gap extension= 0, match=5, mismatch=−4,
no end gap penalty) to align all assigned reads to the loci/amplicon
sequence. Subsequently, primerdimer reads are removedbydetect-
ing deletions larger than the size of the amplicon, subtracting the
lengthof the twoprimers anda short buffer.Additionally, sequenc-
es that contain a high number of indels or mismatch events com-
pared with the remainder of the reads are filtered as these are
potential sequencing artifacts or originate from off-target amplifi-
cation (Supplemental Note S8; Supplemental Fig. S19). Mutation
frequencies are calculated from the remaining reads using the fre-
quency of indels that (Supplemental Fig. S14) overlap a region (±
5 bp) around the expected cut site. If paired-end sequencing is
used, ampliCan follows consensus rules for the paired forward
and reverse read, generallypicking the readwith thebest alignment
in case of disagreement (for description, see Supplemental Figs.
S20, S21). The alternative strategy of merging the paired reads is
supported by ampliCan but has been shown to be detrimental to
performance (Lindsay et al. 2016). The expected cut site can be
specified as a larger region for nickase or TALEN experiments in
which the exact site is not known. Any indel or mismatch also ob-
served above a 1% threshold in the control is removed. Frameshifts
are identified by summing the impact of deletions and insertions
on the amplicon.
A series of automated reports is prepared in form of “.Rmd”
files, which can be converted tomultiple formats but also immedi-
ately transformed into HTML reports with knitr (https://yihui
.name/knitr/) for convenience. There are six different default re-
ports prepared by ampliCan with statistics grouped at the corre-
sponding level: identifier, barcode, gRNA, amplicon, summary,
and group (user-specified, but typically signifies the researcher
conducting the experiment, treatment of sample, or other group-
ing of interest). In addition to alignments of top reads (Fig. 1C;
Supplemental Fig. S5), reports contain plots summarized over all
deletions, insertions, and variants (Supplemental Fig. S14). In ad-
dition, a number of plots showing the general state of the experi-
ments is shown, including the heterogeneity of reads to
investigate mosaicism or sequencing issues (Supplemental Figs.
S13, S22, S23) and overviews of how many reads were filtered/as-
signed at each step (Supplemental Fig. S24). In addition to the de-
fault plots, ampliCan produces R objects that contain all
alignments and read information; these can be manipulated, ex-
tended, and visualized through the R statistical package.
ampliCan provides a versatile tool that can be used out-of-
the-box or as a highly flexible framework that can be extended
to more complex analysis. The default pipeline consists of a single
convenient wrapper, amplicanPipeline, which generates all de-
fault reports. More advanced users can gain complete control
over all processing steps (Supplemental Fig. S25) and produce nov-
el plots formore specialized use cases. Compatibilitywith themost
popular plotting packages ggplot2 (https://ggplot2.tidyverse.org)
and ggbio (Yin et al. 2012), as well as the most popular data pro-
cessing packages dplyr (https://dplyr.tidyverse.org) and data.table,
provides a full-fledged and elastic framework. Output files are en-
coded as GenomicRanges (Lawrence et al. 2013) tables of aligned
read events for easy parsing (Supplemental Table S5) and hu-
man-readable alignment results (Supplemental Table S4) and
FASTA. We would like to encourage users to communicate their
needs and give us feedback for future development.
Running parameters
Supplemental Code S1 and https://github.com/valenlab/ampli
can_manuscript both contain all code related to reproducibility
of benchmark and analyses. For benchmarking, all the tools were
used with their default options; specific versions of the tools and
software can be found in the description file.
Software availability
ampliCan is developed as an R package (R Core Team 2018) under
GNU General Public License version 3 and is available through
Bioconductor under http://bioconductor.org/packages/amplican
or https://github.com/valenlab/amplican. Supplemental Code S2
contains ampliCan source for installation, version 1.5.6.
Data access
All real data sets from this study come from the zebrafish TLAB
strain and have been submitted to the NCBI BioProject database
(BioProject; https://www.ncbi.nlm.nih.gov/bioproject/) under ac-
cession number PRJNA245510 (run 1 and run 5). Other data sets
used in this study, published previously, are described in the
SupplementalMaterial. Descriptions, treatments, and other details
of those data sets were previously described (Gagnon et al. 2014).
Synthetic data sets can be reconstructed with the use of code
from https://github.com/valenlab/amplican_manuscript (Supple-
mental Code S1). Synthetic data sets were created in a similar fash-
ion to the sets previously described (Lindsay et al. 2016) using 20
different loci edited at variable efficiency (0%, 33.3%, 66.7%,
and 90%) and with the possibility of adding HDR. Further details
can be found in the Supplemental Material.
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Availability of code and data  
All code and configuration files used for the analyses in this manuscript are available at                             
https://github.com/valenlab/amplican_manuscript where they can be used for independent               
verification. Copy of this repository is also available as ​Supplementary Code S1 ​. Data                         
analysed is publicly available and accessible at their respective accession numbers. ampliCan                       
is available from Bioconductor as the R package at                 
http://bioconductor.org/packages/amplican ​. To obtain the newest development version visit               
https://github.com/valenlab/amplican ​. 
Data Overview 
In this manuscript we have used multiple datasets, both real and simulated. Real datasets from                             
Gagnon et al. 2014, runs 6-10 (accessible under E-MTAB-6310, E-MTAB-6355, E-MTAB-6356,                     
E-MTAB-6357, E-MTAB-6358) were supplemented with our experiments for a total of 263 loci.                         
All experiments had a control sample where no guideRNA was injected (accessible under                         
BioProject PRJNA245510, run 1 and run 5). This dataset was used to highlight importance of                             
controls as well as differences between the tools. The data is further discussed in                           
Supplemental Note S1 ​. Additional real data from ~ 1400 loci from Chari et al. 2015 was used                                 
for assessment whether large deletions can happen in real experiments.  
 
Simulated datasets were created using a strategy similar to Lindsay et al. 2016 where CRISPR                             
editing is emulated based on distributions of events (mismatches, deletions and insertions)                       
from real experimental data (20 loci from ​(Shah et al. 2016)​). FASTQ files were created using                               
ART ​(Huang et al. 2012) where qualities were set to be uniformly high. Configuration files were                               
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created using base loci sequences, same as used for CRISPR editing simulation. This data is                             
further detailed in ​Supplemental Note S4 ​. Complete overview of all datasets is presented in                           
Supplemental Tab S6 ​. 
 
Supplemental Note S1: Tools differ in estimating editing efficiency on real data. 
We assessed how tools estimate editing efficiency on 263 real CRISPR experiments, of which                           
151 were previously published by us ​(Gagnon et al. 2014)​, datasets from run 1 and run 5                                 
available at BioProject under accession number PRJNA245510), and 112 novel experiments                     
from 5 sets for this study (datasets from run 6-10 available at ArrayExpress: E-MTAB-6310,                           
E-MTAB-6355, E-MTAB-6356, E-MTAB-6357, E-MTAB-6358). All experiments were conducted               
by injection into 1 cell zebrafish embryos and sequenced 2 days post-fertilization ​(Gagnon et                           
al. 2014)​. Due to the rapid cell division and development these experiments are likely to result                               
in highly heterogeneous mutational efficiencies from mosaicism. For these experiments the true                       
mutation efficiency is not known and we can therefore not assess how precise the tools are in                                 
their estimates. Instead, we quantified how much the tools differ in their estimates                         
(​Supplemental Fig S1A) ​and, to qualitatively assess the underlying reason for their                       
discrepancy, we plotted the estimated mutation efficiency values of the tools relative to the                           
non-normalized ampliCan result (​Supplemental Fig S1B​). This showed that discrepancies are                     
likely to originate from different causes. Some, those above the normalized ampliCan estimate,                         
likely stem from a failure to consider control experiments. In our data the experiments                           
impacted by controls is about 5%, but this will depend heavily on the reference genome,                             
heterogeneity of the region and organism under study. Specific examples of the importance of                           
normalization are shown in ​Supplemental Fig S5 ​. The discrepancies of the other experiments                         
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are due to the steps in the processing pipeline, e.g. off-target detection, primer dimer filtering,                             
alignment strategy and read merging. To investigate the specific sources of these                       
discrepancies and quantitatively assess the performance of the tools we created several                       
synthetic benchmark datasets.  
Supplemental Note S2: Automatic normalization using control reads 
By default ampliCan normalizes through the strict removal of all editing events (insertions,                         
deletions, mutations) that are also found above a threshold in the control sample. The default                             
threshold value is a frequency of 0.01 and was chosen based on the typical frequency of                               
low-abundance editing events (‘background noise’) present in control experiments                 
(​Supplemental Fig S4 ​). These events are assumed to be technical or experimental artifacts                         
present in most experiments. The threshold is also selected to be well above the expected                             
Illumina error rate ​(Ross et al. 2013)​. 
 
The threshold can be adjusted to increase the precision of indel detection when sequencing                           
depth is high or account for a higher error rate in low-depth/precision experiments. The                           
threshold can be set for instance based on the background error in the user’s own control                               
experiments or in the absence of controls by inspecting the error rate outside of the target site                                 
(see for instance in ​Supplemental Fig S14A​). Alternatively, if the user has information about                           
the level of variance or noise expected in the case and/or the controls (e.g. genetic variance                               
restricted to 100% or 50%) the threshold can be raised for increased stringency. This may in                               
particular be useful if the user expects high frequency background events in the control                           
experiments. One such use case is if index hopping is likely to be an issue. Index hopping may                                   
cause reads from the edited sample to erroneously be assigned to the control sample. We                             
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therefore offer a second pipeline ‘amplicanPipelineConservative’ for experiments where this is                     
expected to be a problem featuring a more stringent threshold of 0.15. For more information                             
about index hopping and how to mitigate the problem see Illumina’s webpage                       
(​https://www.illumina.com/science/education/minimizing-index-hopping.html ​, Accessed   
January 22, 2019). 
 
Given that the sequencing depth is sufficient the default settings should allow detection of                           
indels as low as 0.01% (​Supplemental Tab S5 ​). If higher accuracy is necessary this threshold                             
can be lowered and the sequencing depth increased. In the extreme case of setting the                             
normalization threshold to 0% any event found in control would be removed from the case                             
sample. This may result in removal of real edits and consequently the underestimation of real                             
editing events.  
 
Due to the stochasticity in sequencing data this approach is better suited to handle more                             
heterogeneous cases than the subtraction method where indel frequency is simply normalized                       
by subtraction of the control indel frequency. In the latter case variation in the levels of indel                                 
frequencies in the control versus CRISPR treated samples can lead to partially normalized                         
data. Both normalization methods are outlined in ​Supplemental Fig S2 while ​Supplemental                       
Fig S3 shows examples of highly heterogeneous data where without normalization estimated                       
mutation efficiency would be biased. Normalization becomes even more important when the                       
exact nature of the indel event matters, for instance whether it induces a frameshift or not                               
(​Supplemental Fig S5 ​). Examples in ​Supplemental Fig S5 can be recreated with the use of                             
“make_comparison_normalized.Rmd” in the amplican_manuscript repository. 
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As a test for the normalization method we calculated the (non-existent) mutation frequency of                           
the control samples normalized by the CRISPR-edited samples in order to see if false positives                             
were generated. This was accomplished by 1) only considering the region between the                         
sequence complementary to the guide RNA and the primer-matching sequence, and 2)                       
excluding all large deletion events (>10bp) which could extend beyond the boundaries of this                           
region. This resulted in a mean estimated mutation frequency of 0.0038 (median of 0.0012),                           
well below the detection limit for the standard settings of 0.01. 
 
Supplemental Note S3: ampliCan utilizes optimized alignments  
CRISPR genome editing events typically result in a single break at a single site and by                               
extension produce a single deletion and/or insertion. Sequence read aligners are generally not                         
optimized for this type of genome editing event which can lead to the aligner fragmenting the                               
indels and creating multiple events (example in ​Supplemental Fig S6 ​). In the worst case                           
fragmented alignments could shift the indel events resulting in a distortion of the mutation                           
efficiency for those tools that only allow events within a certain distance from the expected                             
site. A more likely outcome however, is the misinterpretation of the nature of the mutation.  
Under certain assumptions the theoretically optimal alignment can be obtained by the                       
Needleman-Wunsch algorithm. ampliCan uses this algorithm with optimized parameters to                   
reflect the expectation that a CRISPR experiment should result in one deletion and/or insertion                           
event, of unknown length (match = 5, mismatch = -4, gap opening = 25, gap extension = 0, no                                     
end gap penalties). With these parameters the Needleman-Wunsch algorithm performs well                     
over a broad range of test cases (data not shown). ampliCan uses these optimized parameters                             
6 
by default, but also allows for supervision of the alignments through human readable output of                             
individual alignment results (​Supplemental Table S4 ​). 
Supplemental Note S4: Synthetic data set evaluation 
The latest available versions was used for all tools and packages. The assessment set from                             
Lindsay et al. ​(Lindsay et al. 2016) paper (Synthetic Dataset 2, Supplemental 4) was replicated                             
with the same settings and seed values as described (​Supplemental Fig S7 ​). The script from                             
Lindsay et al. 2016 was used for parsing, but a small bug in the code was fixed for the                                     
CRISPResso output. In Lindsay et al. only NHEJ estimation of mutation efficiency was                         
considered for CRISPResso, skipping HDR and “mixed” mutation frequencies. However, fixing                     
this error did not influence CRISPResso’s overall performance in any significant way. Versions                         
of tools, scripts and details needed for replication are available in the                       
https://github.com/valenlab/amplican_manuscript repository. ampliCan used the same           
amplicon sequences as CRISPResso.  
 
It should be noted that Synthetic Dataset 2 from Lindsay et al. 2016 (used for ​Supplemental                               
Fig S7 ​) is not a good approximation of a real life situation. First, the sequence matching the                                 
primers can not be very divergent as they would then fail to amplify. Second, several                             
experiments are badly designed in that the target sites are very close to the sequencing end of                                 
the reads. This makes it difficult to correctly call indels with support from both paired reads.                               
Third, paired-end sequencing of 200bp or longer is somewhat expensive and error-prone and                         
most labs would seek to restrict this to shorter reads. To account for this we created an                                 
additional set, Synthetic Dataset 3, in a similar fashion to Synthetic Dataset 2, but with with the                                 
following minor modifications. First, the length of amplicons and reads (150 bp) were adjusted.                           
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Second, gRNA target sites were designed to be covered by both reads. Third, PCR off-target                             
reads were created without mutating the primer sequences. Finally, mutation efficiency was                       
tested across a range of mismatch rates, 10%, 20% and 30% (​Fig 2 ​, Supplemental Fig S8 ​), to                                 
reflect different levels of similarity to the contaminant reads.  
 
For Synthetic Dataset 2 ampliCan matches the perfect score of CrispRVariants and                       
AmpliconDivider. However, on Synthetic Dataset Dataset 3 ampliCan is more consistent at                       
estimating the known mutation efficiencies within the dataset (​Fig 2 ​). AmpliconDIVider has no                         
filtering step and is confused by the contaminating reads. CrispRVariants has a filtering step,                           
but is unable to discern divergent off-target sequences (e.g. homologous regions) that are still                           
able to align to the correct target site. As in the benchmark from Lindsay et al. 2016                                 
CRISPResso performs poorly on all benchmarks. When increasing mismatch rate (from 10% of                         
all bases to 20% and 30%), AmpliconDIVider and CrispRVariants get closer to the correct                           
estimated indel rate, but in all cases ampliCan obtains the highest precision and shows the                             
most robust performance (​Fig 2 ​,​ Supplemental Fig S8 ​).  
Supplemental Note S5: ampliCan is able to correctly call longer indels  
We have found that even without targeted insertion CRISPR mutagenesis can frequently result 
in some proportion of longer indels (​Supplemental Fig S9 ​). In particular, we have observed 
unintended insertions from lentiviral vectors used to introduce the guides and Cas9 
(​Supplemental Fig S10 ​, ​(Chari et al. 2015)​.  
 
Current tools primarily rely on either global mapping (CrispRVariants, AmpliconDIVider)                   
(​Supplemental Tab S1 ​) that can have problems identifying the correct loci in the presence of a                               
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larger insertion or have certain processing steps that are incompatible with longer events (see                           
below for CrispRVariants). This mitigates primer dimer contamination problems (which can be                       
identified by too large deletion gaps after alignments), but ignores bona fide large indels. These                             
tools are therefore often unable to handle longer indels whether unintended or targeted. Long                           
deletions are also a problem for some tools. For instance, CrispRVariants filters out any                           
deletion that does not start or end within the gRNA complementary sequence plus a buffer of 5                                 
bp. Any deletion spanning this region is ignored. This can be used as a strategy to filter                                 
primer-dimers, but also has the side-effect of ignoring any bona fide longer deletions.                         
ampliCan uses a local alignment strategy that can detect these longer indels and a more                             
realistic model of primer-dimer artifacts (​Supplemental Note S8 ​).  
 
We noticed that in the Synthetic Dataset 2 from Lindsay et al. 2016 (CrispRVariants benchmark                             
dataset) large indels (>10 bp) were disabled. To assess the capabilities of leading tools in                             
handling longer indels we created Synthetic Dataset 4. We made three subsets: 1) with no                             
indels > 10bp, 2) with a mix of indels by simply removing the line disabling longer reads in the                                     
Lindsay et al. script. 3) To check explicitly how tools handle experiments with planned shorter                             
insertion of donor sequence we created a third scenario described as “insertions > 10bp” on                             
the figure. 4) For completeness we also created a set of large deletions. ampliCan match the                               
best competitors on the the set with no long indels and consistently outperform the other tools                               
on the mixed set and the set only containing long indels (​Fig 2 ​, ​Supplemental Fig S11 ​). 
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Supplemental Note S6: ampliCan consistently recovers the true HDR efficiency                   
when faced with diverse donor templates 
ampliCan takes into account the donor template and the original genomic sequence to define                           
the set of events that corresponds to a correct HDR editing experiment, but allowing for some                               
background sequencing noise (currently 3 mismatches by default). This is unlike CRISPResso,                       
the other CRISPR tool that can handle HDR events, which do not model events but simply                               
align reads against donor and original sequence picking the best-scoring instance. The                       
advantage of ampliCan’s approach is that it accounts for alignment imperfections in a more                           
robust fashion, allowing for complex donor-amplicon relations and sequencing errors. 
 
We designed a dataset for benchmarking the HDR calling capabilities of the most popular                           
tools. Using the same loci as in ​Supplemental Note S1 we tested 20 different donor templates                               
for each of three kinds of donor types: with point mutations, insertions or deletions of variable                               
length from 5bp to 70bp introduced into the amplicon sequences. We simulated 2000 reads                           
with different levels of HDR efficiency rate (0, 33, 66, 90). In this benchmark set only ampliCan                                 
makes no errors (​Supplemental Fig S12 ​).  
Supplemental Note S7: Visualization and aggregation of the complete activity of                     
gRNAs 
While the default alignment plot shows the most abundant reads across the expected cut site it                               
doesn’t provide an overview over all editing events. ampliCan therefore also produces multiple                         
plots that aggregate and visualize editing events (​Supplemental Fig S14 ​). Unlike the alignment                         
plots these show the complete activity of the gRNA allowing for comparison of gRNAs by                             
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manual inspection. The pipeline in ampliCan treats forward and reverse reads separately                       
which, after visualization, makes it possible to spot read-related problems immediately                     
(​Supplemental Figs S21, S22 ​, ​S23 ​). In addition, ampliCan provides meta plots that aggregate                         
information across groups of experiments allowing for visualization of deletions, mismatches or                       
insertions across groups of gRNAs, amplicons or any other set. This can for instance show the                               
combined activity of a single guide across multiple experiments.  
 
ampliCan builds on top of ggplot2 ​(Wickham 2016) package and provides higher level                         
functions that automatically group event data (eg. collapse on start and end of deletion) and                             
plot results. Users can extend those plot objects and treat them like any other ggplot2 object.                               
ampliCan supports multiple types of meta plots to facilitate comparison of not only the gRNAs,                             
but also any group that a user wants e.g. barcode, amplicon, type of treatment (​Supplemental                             
Figs S3 ​, ​S17 ​, ​S18 ​).  
Supplemental Note S8: Filtering of noise  
Multiple sources of noise can confound the estimation of cut rates, low quality reads,                           
primer-dimers, PCR off-target amplification and sequencing artifacts. ampliCan has three filters                     
to remove noise from different sources: 1) low quality reads, 2) primer-dimers, and 3)                           
erroneously assigned reads and sequencing artifacts. 
Low quality reads  
ampliCan offers basic read quality overview with the use of ShortRead ​(Morgan et al. 2009)                             
package and filters for minimum base quality (default: 0) in a read, average base minimum                             
quality (default avg min: 30) and the presence of ambiguous (N) letters. 
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Primer-dimers  
Filtering primer-dimers is a balance between getting rid of erroneous reads and allowing for                           
longer deletions. For instance, CrispRVariants ignores all alignments with deletions larger than                       
33 bp (the guide plus a buffer of 5 bp) and is frequently unable to map long insertions (​Fig 2B​,                                       
Supplemental Fig S11 ​). This effectively removes all primer dimers, but also ignores any bona                           
fide longer indels. ampliCan instead tries to estimate the likely length of a primer dimer deletion                               
by taking the length of the amplicon, subtracting the primer lengths with a small buffer (30 bp)                                 
to arrive at maximally allowed deletion length. This results in a more realistic estimate of the                               
length of artificial deletions that would result from primer-dimers. As an example, for an                           
amplicon of size 150 with primers of length 20, the maximum deletion length would be 80 bp                                 
(150-(2*20+30)). 
Erroneously assigned reads and sequencing artifacts 
An assumption of ampliCan is that a CRISPR editing event will result in a low number of indel                                   
events resulting in a good alignment with few discrepancies to the reference sequence or (if                             
available) the control experiment. To accomplish this ampliCan uses a two dimensional                       
clustering method based on sequence alignment score and sequence alignment indel events                       
to filter out erroneous reads and sequencing artifacts. This takes all alignments and performs                           
k-means clustering with different 1-3 clusters. It then uses the silhouette criterion to determine                           
the optimal number of clusters. In the case of 1 cluster, all reads are either edited or perfectly                                   
matching the reference/control. In the case of 2 you have both edited and unedited reads. In                               
the case of 3 clusters, cluster with center that has the biggest number of events and lowest                                 
alignment score (in normalized relation on 0-1 scale) means that you in addition have a group                               
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of sequencing artifacts or reads that poorly align to the loci (example in ​Supplemental Fig                             
S19 ​). 
 
ampliCan provides plots that shows the impact of each of the filtering steps, across the whole                               
library for read quality (​Supplemental Fig S16 ​) and for each experiments for primer-dimer and                           
assignment/artifacts issues (​Supplemental Fig S15 ​). 
Supplemental Note S9: Read assignment  
ampliCan assigns reads to the respective experiment by matching primers used in the                         
amplification of the loci. These region should be immutable and match the reads since an indel                               
spanning a primer would either result in failure to amplify the locus or be “corrected” by the                                 
primer when it amplifies the target site. However, since small sequencing and primer synthesis                           
errors could potentially occur in the primer part ampliCan allows for up to 2 mismatches (user                               
customizable) between the primers and reads. During this process it is possible that some                           
reads will be unassigned and not match any of the experiments. While these reads are typically                               
noise from the high-throughput nature of the sequencing experiment, they could in some cases                           
be helpful in troubleshooting failed experiments. ampliCan therefore provides human readable                     
alignments of the top 5 most abundant forward and reverse read pairs aligned to each other                               
(​Supplemental Fig S24 ​). In some cases these correspond to off-target PCR amplicons and                         






Supplemental Fig S1. Comparison of leading tools on real CRISPR experiments. ​A. Summary of                     
differences between ampliCan and other tools. CrispRVariants reports similar editing efficiencies                     
to ampliCan in ~80% out of 263 experiments. The remaining experiments are due to controls                             
(~5%) and processing (~15%) ​B. Experiments (x axis, sorted) where estimated mutation                       
efficiency differs by at least 5% from non-normalized data. y-axis shows differences in relation                           
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to non-normalized ampliCan estimates. Differences between tools predictions staying above line                     
created by ampliCan prediction are likely to be due to lack of normalization, while the                             
predictions below the ampliCan are likely due to the alignments, processing and filtering of data. 
 
 
Supplemental Fig S2. Two common methods for normalization using controls. In the first, the                     
frequencies from events in the control sample are subtracted from the frequencies in the treated                             
sample (subtraction method). In the second method, all events occurring in the control above a                             
frequency threshold (ampliCan default: 1%) are removed from the treated sample. The latter is                           
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Supplemental Fig S4. Distribution of the frequency of events in the control sample of real                       
experiments. The vast majority are low frequency events likely to be technical and                         
experimental artifacts. ampliCan uses a threshold to exclude these so they are not                         
considered for normalization. The default threshold is a frequency of 0.01 which                       
excludes more than 99% of these events as noise. These low-abundance events are                         
therefore not considered when normalizing the target loci. If the user know the level of                             




Supplemental Fig S5. Example of normalization with controls on 3 real experiments. In                   
heterogeneous data it can be challenging to derive the true mutation profile. ​A. ampliCan                           
automatically removes wild type mutations and reduce the number of frameshift inducing                       
mutations from 68% to 36%. ​B. A large number of insertions could be mistaken for CRISPR                               
activity reducing the total indel rate from 53 % to 3 %. ​C. A large fraction of reads (39%) carry a                                         
G instead of an A. This mismatch also occur at high frequency in the control and is therefore                                   
18 
assumed to represent genetic variance. The mismatch is ignored and the reads are merged with                             























































































































































































































































































































































































































































Supplemental Fig S7. ampliCan outperforms CrispRVariants on its own synthetic dataset. ​A.                 
Performance of leading tools when facing different mutation efficiencies and fractions of                       
contaminating reads. The sets are obtained from the benchmark data in ​(Lindsay et al. 2016)                             
(CrispRVariants), Synthetic Dataset 2 (Supplemental Fig. 15 in ​(Lindsay et al. 2016)​. Each dot in                             
the plot correspond to the estimated mutation efficiency calculated by a single tool for a single                               
experiment, while the dotted line shows the true mutation efficiency The fraction of contaminant                           
reads varies on the x-axis. ​B. Error rates (​C. log10 scaled) of the same experiments. The median                                 
error is indicated by the horizontal line.  
21 
 
Supplemental Fig S8. The data from left panel of Fig. 2 split by the true mutation efficiency and                             
with a baseline of 0% true mutation efficiency added for comparison. The dots shows estimated                             
mutation efficiency by leading tools on reads with increasing contamination (as 0, 10 and 25                             
percentage of all reads) with different mismatch rate of the off-target reads (10%, 20%, 30%).                             
Each point corresponds to one experiment. True mutation efficiency is indicated with dotted                         
lines, and labelled to the right of the charts. Contamination is simulated by introducing random                             
mismatches (Contaminant read mismatch rate) in reads mapping to the loci, similar to the                           
benchmark in ​(Lindsay et al. 2016)​. The mismatch rate is indicated at the top. Only ampliCan                               
shows robustness to the whole range of different mismatch rates and mutational efficiencies.  
22 
 
Supplemental Fig S9. Fraction of reads having indels greater than 10 bp across 176 experiments.                       
Each dot represents one experiment and are grouped in rows by having the same gRNA                             
23 
(replicates). All experiments are normalized using wild type controls ensuring that these are real                           
indel events. ​The ​higher mean for some of the replicated experiments ​suggests that some                           
gRNAs have a higher chance of resulting in long indels. 
 
 
Supplemental Fig S10. Distribution of insertions width for lentiviral samples on Chari et al. 2015                         
datasets. Shows the proportion (y-axis) of reads with a given insert length (x-axis). The insert                             
shows a population of unintended larger insertions. Around 90% of these originate from the                           




Supplemental Fig S11. Performance ​of leading tools grouped on simulated data with large indels.                       





Supplemental Fig S12. Performance of ampliCan, CRISPResso and CRISPRessoPooled on               
simulated data with variable donor templates, variable true HDR read rate (0, 33, 66 %) and                               
variable NHEJ editing (0, 10, 33 %). The dotted lines represents the real HDR (vertical) and NHEJ                                 
(horizontal) efficiencies and their intersection the correct estimate of both. The performance on                         
20 donors of different types (mismatch, insertions and deletions) and of variable length (from                           
5-70bp) were averaged into a single dot for visibility. While ampliCan handles donor templates                           





Supplemental Fig S13. Example of a heterogeneity plot produced by ampliCan. In this, identical                       
reads are collapsed together and grouped by gRNA. A stronger shade of yellow indicates a large                               
group of homogeneous reads. This plot can give insight into the heterogeneity of the outcome. A                               
high level of heterogeneity can indicate sequencing problems or mosaicism. Reads can also be                           





































































































































































































































































































































































































Supplemental Fig S15. ​Example of bar plot showing fraction of reads that were filtered out of the                             
experiments. Red bars correspond to a primer-dimer filter, and blue bars indicate low quality                           
reads. 
 
Supplemental Fig S16.  ​Waffle plot of the quality of reads across all experiments.  
30 
 
Supplemental Fig S17. ​Example of comparison plots in ampliCan test data where Indel rates are                         
grouped by the researcher performing the experiments. These can be grouped on any user                           
specified criteria. 
 
Supplemental Fig S18. ​Example of a deletion metaplot produced by ampliCan summarizing                   
multiple experiments. Here, an aggregation of editing events from many experiments (many                       
targets) using the same gRNA is presented giving an overall gRNA cut profile. Position 0 is                               




Supplemental Fig S19. ​Example of k-means clustering of reads during filtering of contaminant                     
reads. A low alignment score (x axis) combined with a high number of events (y axis) indicate                                 
erroneous reads. Silhouette criterion is used to determine whether data should be clustered into                           
two (read with no edits and reads with editing events) or three clusters (a noise cluster). In the                                   





Supplemental Fig S20. ​The paired-end read consensus rules for ampliCan. Events marked in green                       
are considered real cut sites while those in gray are not. When reads from forward (purple) and                                 
reverse (blue) reads are in agreement there is a consensus (top row). When two reads overlap,                               
but disagrees the event from the strand with a higher alignment score is used (row 2). In                                 
situations where an event is only covered by one read, that read is preferred (row 3). In rare                                   
cases where there are events on one strand and the other has continuous alignment ampliCan                             




Supplemental Fig S21. ​Percentage of reads with ambiguous indels caused by disagreement of                     
forward and reverse reads. ampliCan consensus rules help to mitigate mis-estimation that could                         
arise from these events. 
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Supplemental Fig S24. ​Screenshot of the example barcode report, top unassigned read section.                     
Human readable alignment of forward and reverse reads of the top most frequent unassigned                           
reads is presented. Huge fragmentation and poor alignment suggest contamination, while low                       
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1  100  100  100  0 
10  10  10  10  0 
100  1  1.001001001  1.001001001  0 
1000  0.1  0.1102093979  0.1001903617  0.0100190362 
10000  0.01  0.0260724815  0.0100278775  0.016044604 
100000  0.001  0.0187490099  0.0010026209  0.0177463891 
 
Supplemental Table S1. Table displaying precision of the ampliCan when detecting editing                 
events with variable normalization threshold. ampliCan can be used to identify extremely low                         
frequency (0.001% and potentially lower) editing, but requires use of no normalization threshold                         
(0%, below Illumina sequencing noise and alignment imperfections). Default normalization is set                       
to 1% (above standard Illumina noise) and is recommended for standard applications as this                           
setting negates the chance of removal of real editing events due to random sequencing and                             
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Chari et al. 2015  Example of large 
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As in Lindsay et al. 
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Synthetic Dataset 4, 
20 loci x 4 efficiency 
rates x 4 types of 
indels = 320 
experiments 
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Precision of ampliCan  Supplemental Tab S8. 
 













(Lindsay et al. 2016) 
BWA-MEM​(Li 2013) 
as global alignment 
Filters primer dimers by restricting start/end 
of indel, but may result in missing larger 
deletions. Larger insertions can be missed 
through mapping. 
ampliconDIVider  




Sometimes returns estimates above 100%, 
these values were filtered. We run only the 
variant counting step of the pipeline. The full 
pipeline requires the commercial novoAlign.  
CRISPResso & 
CRISPRessoPooled  




Poor performance due to unknown issues. It 
was installed and run in the same fashion as 









Supplemental Table S4. ​Example of human readable output. Aligned reads are assigned to                    
the experiment (ID, read_id) and sorted based on count (Count). For each pair alignment is                             
presented with top part representing forward read aligned to amplicon and bottom presenting                         




Supplemental Table S5. Example GenomicRanges table output with additional           
meta-columns. This representation of alignments allows for efficient manipulation and                   






Supplemental Table S6. Example ampliCan config file. ampliCan requires this file as minimal                   
input, together with relevant fastq files. More precise, up to date description of the file can be                                 
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7. Conclusions and future perspectives 
 
Scientific software should be intuitive to use by a group of researchers that do not need 
to understand all of the details, yet at the same time provide opportunities for 
optimization by seasoned experts. Scientific tools should also be frequently updated to 
match the speed of the developing field of genome editing. I believe I adhered to this 
goal with both CHOPCHOP and ampliCan, which are designed to contain current 
advances in the field. At the same time, it cannot be stressed enough that the usefulness 
of even the most wonderful tool can be hindered by proprietary rights, therefore all 
programs presented in this thesis are completely free to use by academic and non-profit 
users. 
 
In the era of a reproducibility crisis in science, state-of-the-art bioinformatics tools can 
gain quality with thorough benchmarks and continuous updates. Currently, the field of 
designing CRISPR gRNAs is quickly developing. Novel methods are published as 
feature-incomplete tools. Meanwhile, CHOPCHOP tries to include recent advances 
with continuous updates, not satisfied with just maintenance.  
 
Ideally, CHOPCHOP would be reimplemented in the future with better memory usage 
and multi-core support. CHOPCHOP could be further improved with integration of 
precomputed databases of tested guideRNAs e.g. Brunello (Sanson et al. 2018). 
Definitive improvements to the off-target search could also be made, for instance, 
integration of SNP databases for better awareness of genome heterogeneity (Haeussler 
et al. 2016). Allowing for more than 3 mismatch off-target searches, as well as searches 
with bulges requires a specialized aligner (Bae, Park, and Kim 2014), and together with 
the latest off-target scoring algorithms would elucidate more comprehensive off-target 
searches than currently offered. In the future, more robust models for gRNA efficiency 
and repair profile predictions will become available. It will become easier to integrate 
a new machine learning models as the field of machine learning becomes more 





Analysis of the CRISPR edited experiments, especially from amplicon sequencing data, 
has proven to be more challenging than initially expected. ampliCan was created to 
remedy those issues and ensure precision of estimated editing efficiencies. ampliCan 
itself is advocating for event level resolution that builds a framework which could be 
potentially used in other scientific fields. For instance, extraction of events per read is 
sought for in nanopore sequencing to detect modified bases, but currently only 
mismatch pileups on the genomic/transcriptomic level are available (Rand et al. 2017; 
Simpson et al. 2017). The ampliCan methodology could potentially be used to cover 
alignments to the genome, not only to the amplicons, further expanding the range of 
possible applications. 
 
In the future, when computational power is less of an issue, multiple sequence 
alignments (amplicon sequences aligned with forward and reverse reads together) might 
be an improvement to the current alignment strategy of ampliCan. Multiple sequence 
alignment has high potential to solve issues related to mapping, as even with optimized 
alignments, ampliCan can still struggle with some reads with longer indels. When this 
happens or the field develops further, we can also extend the benchmarks to compare 
additional tools such as CRISPR-DAV (Xuning Wang et al. 2017), CRISPR-GA (Güell, 
Yang, and Church 2014), BATCH-GE (Boel et al. 2016) or CRIS.py (Connelly and 
Pruett-Miller 2019). 
 
In summary, bioinformatics tools need to accompany scientific progress. Along these 
lines, my scientific contribution has been the creation of tools to facilitate researchers’ 
use of CRISPR. I hope that the software that I have developed will serve scientists 
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